Conditions: Paraganglioma Pheochromocytoma
Keywords: PARAGANGLIOMA PHEOCHROMOCYTOMA SUNITINIB PHASE II Metastatic or locally advanced malignant paraganglioma Metastatic or locally advanced malignant pheochromocytoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer. Paragangliomas (PGs) are tumours that arise from the para-sympathetic system in the head and neck and sympathetic system in the thorax and abdomen. Paragangliomas that secrete hormones (catecholamines) from the adrenal glands are called pheochromocytomas (PCs). In this study, patients whose disease has advanced or spread despite prior standard therapy, will receive sunitinib for 4-weeks followed by a 2-week rest period, for up to 12 months, in the absence of disease progression. Sunitinib is an investigational drug, which has been shown to shrink tumours in several tumour models. The study will evaluate the efficacy as well as the toxicity profile of sunitinib when used as an alternative treatment for patients with PG/PC tumours.

Detailed description:
This study will be a single arm, open-label, phase II trial of sunitinib in patients with metastatic or locally advanced malignant paraganglioma or phaeochromocytoma. Oral sunitinib (50 mg) will be administered to all patients daily for the first four weeks of a six week study cycle, followed by a 2-week rest. Patients will be assessed for response to study treatment using MRI/CT scans as well as bio-chemical tests, and will receive the study treatment for up to 12 months or until disease progression.

Primary study outcomes include:

To assess the efficacy (response rate) of sunitinib given orally daily for 4 out of every 6 weeks in patients with advanced or metastatic paraganglioma/ pheochromocytoma.

To assess the toxicity of sunitinib in patients with advanced or metastatic paraganglioma/ pheochromocytoma.

To document effects of sunitinib on markers of biochemical activity of advanced or metastatic paraganglioma/ pheochromocytoma.

Arms:
arm 1: Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break

Interventions: intervention 1: Sunitinib
Intervention descriptions: intervention 1: 50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)

Protocol document:
Prot_SAP_000.pdf: 
SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 1 of 56 
 
 
     Version 9.0   
SNIPP STUDY - A INVESTIGATOR INITIATED PHASE II STUDY OF SUNITINIB IN PATIENTS WITH 
RECURRENT PARAGANGLIOMA/ PHEOCHROMOCYTOMA 
 
VERSION 9.0 – June 10, 2014 
 
Principal Investigator 
Dr Jennifer Knox 
Jennifer.knox@uhn.on.ca 
Department of Medical Oncology 
Princess Margaret Cancer Centre 
610 University Avenue 
M5G2M9, Toronto 
CANADA 
 
Co-Investigators 
Dr Anthony Joshua 
 
Anthony.Joshua@doctor.com 
 
Department of Medical Oncology 
Princess Margaret Cancer Centre 
610 University Avenue 
M5G2M9, Toronto 
CANADA 
 
Dr Shereen Ezzat 
sezzat@mtsinai.on.ca 
Mount Sinai Hospital 
4th Floor Rm 437 
600 University Ave 
Toronto, Ontario 
Canada M5G 1X5 
 
Dr Ian Tannock 
Ian.Tannock@uhn.on.ca 
Department of Medical Oncology 
Princess Margaret Cancer Centre 
610 University Avenue 
M5G2M9, Toronto 
CANADA 
 
Dr. Monika Krzyzanowska 
Monika.Krzyzanowska@uhn.on.ca 
Department of Medical Oncology 
Princess Margaret Cancer Centre 
610 University Avenue 
M5G 2M9, Toronto 
CANADA 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 2 of 56 
 
 
     Version 9.0   
Dr. Harold Olney 
harold.olney.chum@ssss.gouv.qc.ca 
CHUM – Hopital Notre Dame 
1560 Sherbrooke St East, 
Montreal, QC H2L 4M1 
CANADA 
 
Dr. Isabelle Bourdeau 
isabelle.bourdeau@umontreal.ca 
CHUM – Hopital Notre Dame 
1560 Sherbrooke St East, 
Montreal, QC H2L 4M1 
CANADA 
 
Dr. Dean Ruether 
Dean.ruether@albertahealthservices.ca 
Alberta Health Services 
Calgary, AB  
CANADA 
 
Biostatistician 
Lisa Wang 
Lisa.wang@uhnres.utoronto.ca 
Department of Biostatistics, 
10-511-2 
Princess Margaret Cancer Centre 
610 University Avenue 
M5G2M9, Toronto 
CANADA 
 
 
Pathologists 
Dr. Sylvia Asa 
Sylvia.Asa@uhn.on.ca 
Laboratory Medicine Program 
Toronto General Hospital 
200 Elizabeth Street, 11th floor 
M5G 2C4, Toronto 
CANADA 
 
Dr. Andrew Evans 
Andrew.Evans@uhn.on.ca 
Laboratory Medicine Program 
Toronto General Hospital 
200 Elizabeth Street, E11-223 
M5G 2C4, Toronto 
CANADA 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 3 of 56 
 
 
     Version 9.0   
Pharmaceutical Investigator 
Pfizer Canada 
17300 Trans-Canada Highway 
Kirkland, Quebec, H9J 2M5 
alissa.scalera@pfizer.com 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 4 of 56 
 
 
     Version 9.0   
TABLE OF CONTENTS.....................................................................................................................................................3 
TREATMENT SCHEMA……………………………………............................................................................................5 
SUMMARY.........................................................................................................................................................................6 
 
1.OBJECTIVES OF STUDY ..............................................................................................................................................7 
 
2.BACKGROUND INFORMATION AND RATIONALE................................................................................................7 
 
3.HYPOTHESIS..................................................................................................................................................................9 
 
4.TRIALDESIGN................................................................................................................................................................9 
 
5.STUDY POPULATION...................................................................................................................................................9 
5.1 Inclusion Criteria...............................................................................................................................................9  
5.2 Exclusion Criteria............................................................................................................................................11 
 
6.PRE-TREATMENT EVALUATION/ SCREENING....................................................................................................14 
 
7 REGISTRATION PROCEDURES………...………………………………………………………………………….15 
 
7.1 General Guidelines……………………;…………………………………………………………………….15 
 
7.2 Registration Process………………….……………………………………………………………………...15 
 
7.3 Initial drug ordering and resupply…………………………………………………………………………...15 
 
8.TREATMENT PLAN ....................................................................................................................................................16 
8.1 ChemotherapyTreatment Plan.........................................................................................................................16 
8.2 PatientMonitoring............................................................................................................................................16  
8.3 Dose Adjustments............................................................................................................................................17 
 
8.3.1 Non-hematological events related to Sunitinib…………………………………………………….18 
 
8.3.2 Management of paroxysmal hypertension…………………………………………………………20 
 
8.3.3 Hematological events related to Sunitinib…………………………………………………………21 
 
8.3.4 Other non-hematological adverse events…………………………………………………………..21 
 
8.3.5 Other hematological and non-hematological adverse events………………………………………24 
8.4 Concomitant Therapy ......................................................................................................................................24 
 
9.EVALUATION DURING AND AFTER PROTOCOL TREATMENT.......................................................................26 
9.1Evaluation During Protocol Treatment.............................................................................................................26  
9.2Evaluation After Protocol Treatment ...............................................................................................................27 
 
10. CRITERIA FOR MEASUREMENT OF STUDY ENDPOINTS....…....................................................................27 
10.1Definitions.......................................................................................................................................................27 
10.2Response and Evaluation Endpoints...............................................................................................................27 
10.3Response Duration .........................................................................................................................................29 
10.4Stable Disease Duration .................................................................................................................................29 
10.5Methods of Measurement.................................................................................. ............................................29 
 
10.6Endocrine Response…………………………………………………………………………………………30 
 
11. STATISTICAL CONSIDERATIONS ........................................................................................................................30 
11.1Objectives and Design....................................................................................................................................30 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 5 of 56 
 
 
     Version 9.0   
11.2Primary Endpoints and Analysis ...................................................................................................................30 
11.3Sample Size and Duration of Study...............................................................................................................30 
 
12.PROTOCOL TREATMENT DISCONTINUATION AND THERAPY AFTER STOPPING ..................................31 
12.1Criteria for Discontinuing Protocol Treatment...............................................................................................31  
12.2Duration of Protocol Treatment......................................................................................................................31 
12.3Therapy After Protocol Treatment is Stopped................................................................................................31 
12.4Follow-up Off Protocol Treatment.................................................................................................................31 
 
13. MOLECULAR SUBSTUDY....................................................................................... ...............................................31 
 
14.SERIOUS ADVERSE EVENT REPORTING.............................................................................................................32 
14.1Definition of a Reportable Serious Adverse Event.......…….........................................................................32 
14.2Reporting Requirements ................................................................................................................................32 
14.3Responsibility for Reporting Serious Adverse Events to Health Canada.......................................................33 
14.4Reporting Safety Updates to Local Research Ethics Boards .........................................................................33 
 
15.ETHICAL, REGULATORY AND ADMINISTRATIVE ISSUES ..........................................................................34 
15.1Institution Eligibility for Participation.........................................................................................................34 
15.2Investigator Qualifications ..........................................................................................................................34  
15.3REB (Research Ethics Board) Approval for Protocols............................................................................... 34 
15.4Informed Consent ....................................................................................................................................... 34 
15.5Retention of Patient Records and Study Files ............................................................................................ 34  
 
16. BACKGROUND THERAPEUTIC INFORMATION.............................................................................................35 
16.1Name and Chemical Information..................................................................................................................35 
16.2Chemical Structure .......................................................................................................................................35  
16.3Mechanism of Action ...................................................................................................................................35 
16.4Experimental Antitumour Activity ...............................................................................................................36 
16.5Clinical Experience ......................................................................................................................................36 
16.6Pharmacokinetic and Pharmacodynamic Studies .........................................................................................36 
16.7Safety Issues..................................................................................................................................................37 
16.8Rationale for Starting Dose and Schedule for Phase II.................................................................................39 
16.9Pharmaceutical Data......................................................................................................................................39 
16.10Adverse Events....................................................................’.......................................................................40 
16.11Potential Drug Interaction ..................................................’.......................................................................40 
 
17.REFERENCES...........................................................................................................................................................41 
 
APPENDIX I – STUDY CALENDER……………………............................................................................................43  
APPENDIX II – PERFORMANCE STATUS SCALES/SCORES.................................................................................45 
APPENDIX III – DRUG DISTRIBUTION, SUPPLY AND CONTROL......................................................................46 
APPENDIX IV – NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V3..............................46  
APPENDIX V – NEW YORK HEART ASSOCIATION CLASSIFICATION OF CARDIAC DISEASE...................46  
APPENDIX VI – DRUGS KNOWN TO BE METABOLIZED BY SELECTED CYP450 ISOENZYMES..................47 
APPENDIX VII- COLLECTION/RECORDING OF BLOOD PRESSURE INFORMATION.....................................50   
APPENDIX VIII – CASE REPORT FORM SUBMISSION SCHEDULE……………………………………………..52 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 6 of 56 
 
 
     Version 9.0   
 
TREATMENT SCHEMA  
 
This study will be a single arm, open-label, phase II trial of sunitinib in patients with metastatic or locally advanced 
malignant paraganglioma or pheochromocytoma. Oral sunitinib (50mg) will be administered to all patients daily for the 
first four weeks of a six-week cycle i.e standard scheduling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients receive oral sunitinib 50mg 
daily for 4 weeks followed by a 2-week 
break in repeating 6 week cycles 
Assess response radiologically 
q12 weeks (CT body + any 
other known disease sites) and 
biochemically q12weeks (24-
hour urinary metanephrines, 
catecholamines or serum 
chromogranin A) 
Disease progression: 
Discontinue patient from trial & 
consider other options 
Objective response (CR or PR) or 
stable disease (SD): 
Continue treatment with sunitinib  
28 patients  ≥ 18 yrs , with metastatic or 
locally advanced & unresectable malignant 
PG or PC that meet eligibility requirements 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 7 of 56 
 
 
     Version 9.0   
TRIAL SUMMARY 
 
ELIGIBILITY  
 
• Metastatic or locally recurrent paraganglioma or pheochromocytoma not amenable to curative treatment modalities 
• No prior therapy with antiangiogenic agents or multi-targeted tyrosine kinase inhibitors  
• > 28 days since prior radiation therapy or major surgery  
• Unidimensionally measurable disease  
• No known brain metastases  
• ECOG performance status: 0-2  
• No other concurrent anti-cancer treatment  
• No serious medical conditions or cardiac disease (as specified in protocol)  
• No uncontrolled hypertension  
• Able to take oral medication  
• Must be able to stop prohibited selected CYP3A4 inhibitors/inducers prior to starting sunitinib as  
described in section 5.2 
 
PRE-TREATMENT EVALUATIONS  
 
• History, physical exam, hematology and biochemistry, urinalysis, toxicity/baseline  
symptoms, and (if applicable) pregnancy test (within 7 days prior to registration)  
• EKG (all patients) and LVEF assessed by MUGA > LLN for patients with prior anthracycline exposure,  
prior thoracic radiation or NYHA class II cardiac function (within 21 days prior to registration)  
• Chest x-ray or CT scan, abdominal and pelvic CT scan, other x-rays/scans as clinically indicated (within 28 days)  
 Clinical tumour measurements 
TREATMENT: Sunitinib 50 mg will be administered orally daily for 4 weeks out of every 6 weeks.  
 
ON TREATMENT EVALUATIONS  
 
Day 1 each cycle (within 7 days prior to treatment)  
• Physical exam (weight, ECOG PS, vital signs)  
• Hematology, biochemistry, urinalysis, TSH, T4  
• Toxicity assessment  
 
Twice weekly, first 3 weeks  
• PT/INR/PTT (for patients on low dose anticoagulants or LMW heparin); then as clinically indicated  
 
Weekly, Cycle 1, then every 2 weeks, cycle 2+  
• Blood pressure and heart rate (by nurse or home monitor)  
 
Every 2 weeks  
• Weight and performance status  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 8 of 56 
 
 
     Version 9.0   
Every 12 weeks, end of every even cycle  
• Chest x-ray or chest CT scan, if positive at baseline  
 
• Abdominal and pelvic CT scan (or MRI), if positive at baseline  
• Other x-rays/scans, if positive at baseline and as clinically indicated 
 Clinical tumour measurements  
• Urinary metanephrines, catecholamines or serum chromogranin A (at the end of approximately every 2 cycles) 
• EKG; LVEF (MUGA) are only for patients with class II NYHA, prior anthracyclines or prior thoracic radiation  
 
DURATION OF TREATMENT  
Patients should stop protocol treatment in the following instances:  
• Intercurrent illness which would, in the judgement of the investigator, affect assessments of clinical status  
• Unacceptable toxicity as defined in section 8  
• Tumour progression or disease recurrence as defined in section 10 
• Request by the patient 
• Completion of therapy as outlined in section 12.2  
  
1.0  OBJECTIVES  
 
1.1  
To assess the efficacy (response rate) of sunitinib given orally daily for 4 out of every 6 weeks in patients with 
advanced or metastatic paraganglioma/ pheochromocytoma.  
1.2  
To assess the toxicity of sunitinib in patients with advanced or metastatic paraganglioma/ pheochromocytoma.  
1.3  
To document effects of sunitinib on markers of biochemical activity of advanced or metastatic paraganglioma/ 
pheochromocytoma  
 
2.0 BACKGROUND INFORMATION AND RATIONALE  
  
Paragangliomas (PGs) are highly vascularized tumours that generally arise from the parasympathetic system in the 
head and neck, sympathetic ganglia in the thorax and abdomen, and the adrenal medulla. These latter tumors may be 
functional, secreting catecholamines (pheochromocytomas [PC]).  
 
These tumors can arise as a result of germline mutations in RET, VHL, NF1, and in subunits B, C, or D of the succinate 
dehydrogenase (SDH) genes, which underlie multiple endocrine neoplasia Type 2 (MEN2), von Hippel–Lindau (VHL), 
neurofibromatosis Type 1 (NF1), and familial paraganglioma syndromes Type 4 (PGL4), 3 (PGL3), and 1 (PGL1), 
respectively.  Global expression signatures of a large group of 76 hereditary and sporadic primary pheochromocytomas 
and paragangliomas have been generated. It was found that tumors with VHL and SDHB or D mutations form a single 
genetic expression cluster, which is distinct from “Cluster 2” pheochromocytomas: those with mutations in RET, NF1, 
and novel familial pheochromocytoma variants without a known primary genetic defect. In this series, sporadic 
pheochromocytomas were distributed between the two major clusters. Importantly, novel VHL or SDHB mutations 
were detected in tumors that aligned with Cluster 1, while RET or uncharacterized deletions were identified in tumors 
that segregated with Cluster 2 that had not previously been screened. A pathway-enrichment method, gene-set 
enrichment analysis (GSEA), was then applied to the data to delineate the underlying biological programs embedded in 
each of these clusters and this suggested that cluster 1 tumors were associated with hypoxia and angiogenesis pathways 
whilst cluster 2 tumors were associated with pathways representing abnormalities of protein synthesis and translation as 
well as kinase signalling. 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 9 of 56 
 
 
     Version 9.0   
The genetic mechanism thought to underlie the hypoxic phenotype in type 1 tumors suggests that the accumulation of 
succinate leads to inhibition of proyl hydroxylases that are critical in the hydroxylation and subsequent degradation of 
hypoxia-inducible factor 1 (HIF-1). A similar mechanism is also evident in tumours with defects in VHL, which is 
likewise critical in HIF-1 proteasomal degradation. The accumulation of HIF-1 activates transcription of a number of 
pro-angiogenic factors such as the VEGF family. It is plausible that treatment with a multi-targeted tyrosine kinase 
inhibitor such as sunitinib may have therapeutic utility in this disease. The proven ability of sunitinib to target VEGF 
target kinases suggests that the pseudo-hypoxic drive found in pheochromocytomas/ paragangliomas is identical to the 
VHL related consequences found in renal cell carcinomas. 
 
The treatment of choice for paraganglioma is surgical resection. While many tumors are benign and can be excised 
totally, some can be malignant and behave aggressively. Following primary surgery, should this be technically feasible, 
annual biochemical testing is often done to help rule out metastatic disease, tumor recurrence or delayed appearance of 
multiple primary tumors. Metastases usually present within 5 years after primary surgery, but may also occur after a 
very long time in individual patients. Well-recognized risk factors for malignant disease are large tumor size (>5 cm) 
and tumors with extra-adrenal location 
 
The 5-year survival for patients with malignant PC/PG and distant metastases is less than 50%, but the individual 
course of disease is highly variable. Radical surgery can be difficult to perform on account of distant metastases, often 
localized to the skeleton (70%). In metastatic PC/PG, the main therapeutic goal is often to obtain tumor bulk reduction 
and subsequent control of hypertension. In the palliative treatment of neuroendocrine tumors it has been suggested that 
if the main tumor bulk (80–90%) can be safely excised, this is a recommended therapy.  There are no randomized trials 
demonstrating any survival advantage of debulking (cytoreductive surgery), however a reduced tumor volume may 
facilitate subsequent radio- or chemotherapy. Tumor reduction can also be achieved by other interventional techniques 
such as selective embolization, chemo-embolization, external beam radiation (effective for bone pain), cryoablation, 
and radiofrequency ablation.  
 
Chemotherapy with a combination of cyclophosphamide, vincristine, and dacarbazine (CVD) can provide partial tumor 
responses and palliation of symptoms in some patients with malignant PC/PG but responses are often of short duration. 
Radionuclide therapy has been used in the palliative treatment of these tumours but the optimal dose, schedule and 
availability of this modality is still in evolution.  
 
Sunitinib malate (suntinib; SU11248, SU011248, Sutent®) is a novel multi-targeted, small molecule inhibitor of 
several receptor tyrosine kinases (RTKs) involved in tumour proliferation and angiogenesis, including vascular 
endothelial growth factor receptor-1 (VEGFR-1), -2, and -3, platelet-derived growth factor receptor (PDGFR) alpha 
and beta, stem cell factor receptor (KIT), the tyrosine kinase (TK) receptor encoded by the ret proto-oncogene (RET; 
rearranged during transfection), and fms-like tyrosine kinase 3 (Flt3) (Investigator’s Brochure SU011248, 2008). 
Sunitinib selectively and potently inhibits the class III and class IV split-domain RTKs (Mendel 2003). Potent activity 
was demonstrated in preclinical models against a number of RTK targets, including VEGF and PDGF receptors. In 
subsequent murine xenograft models, growth inhibition against a variety of solid cancers was reported; daily dosing 
was sufficient to produce a persistent inhibition of VEGF- RTK and PDGF-RTK phosphorylation (Mendel 2003).  
 
Early phase I studies in humans established safe and convenient once-daily oral sunitinib dosing schedules, and clinical 
activity was observed (Rosen 2003; Faivre 2006). In subsequent phase II and III clinical trials of patients with 
previously treated GIST and renal cell cancers, impressive response and stable disease rates were reported using single 
agent sunitinib, with a modest toxicity profile (Demetri 2005; Motzer 2006). A phase II study in previously treated 
metastatic breast cancer reported a modest objective response rate, and phase II studies are ongoing with other solid 
tumours including breast, non-small cell lung and prostate cancers (Miller 2005; cancer.gov). Indeed we have recently 
seen a dramatic tumour response in a patient with a high-grade malignant paraganglioma who was inadvertedly given 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 10 of 56 
 
 
     Version 9.0   
sunitinib under the working diagnosis that he had renal cell carcinoma. The diagnosis was revised after the patient 
underwent definitive surgery and more tissue was obtained. Response to sunitinib rendered his large, locally invasive 
renal mass resectable. 
 
The potential utility of an agent that achieves reproducible responses in these tumours is also high; it may facilitate 
surgery, complement cytoreductive techniques, reduce morbidity associated with catecholamine excess and potentially 
extend survival in metastatic disease. Furthermore, compared to chemotherapy, sunitinib is generally well tolerated and 
can be administered for prolonged periods. Therefore should its efficacy be established in PG/PC, it may provide the 
opportunity for patients to obtain enduring disease control. 
 
3.0 HYPOTHESIS 
That sunitinib will demonstrate clinically useful activity in metastatic pheochromocytoma/ paraganglioma  
 
4.0 TRIAL DESIGN  
This is a non-randomized, non-blinded phase II trial of sunitinib in patients with advanced or metastatic recurrent 
paraganglioma or pheochromocytoma.  
 
5.0 STUDY POPULATION  
Canada has a universal public health care policy ensuring equal access to health services for all populations and 
minorities. The population will be defined by the inclusion criteria. 
This clinical study will be centred at Princess Margaret Cancer Centre in Toronto, Ontario, and will include Hopital 
Notre Dame, in Montreal, Quebec and the Alberta Health Services, Calgary, Alberta as participating centres.    
 
5.1 Inclusion Criteria 
 
5.1.1 Histologically or cytologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either 
evidence of metastases or unresectability. 
 
5.1.2 Evidence of recent disease progression radiologically or biochemically or patients with problematic tumour- 
related symptoms despite lack of documented recent radiological or biochemical progression  
 
5.1.2.1 Radiological disease progression will be defined as follows; when any set of paired CT scans of the 
chest, abdomen and pelvis (done within 13 months of each other) are retrospectively reviewed and there is progression 
as evidenced by either any new lesions or at least a 20% increase in the sum of the LD (longest diameter) of target 
lesions (that will then go on to be followed in the trial), taking as reference the smallest sum LD recorded within the 
preceding 13 months.   
5.1.2.2 Biochemical disease progression will be defined as follows; when rate of change equals or exceeds 50% 
increase over a 6 month +/- 1 month period of either or any of 24-hour urinary metanephrines, catecholamines or serum 
chromogranin A  
5.1.2.3 Symptomatic criteria is intended to capture patients whose paraganglioma is clearly causing symptoms 
to patient or clinical signs concerning to the investigator despite the absence of prior documentation of radiological or 
symptomatic progression.  This would include newly diagnosed patients with concerning signs or symptoms.  
Investigators will still attempt to document radioligical or biochemical progression if possible, as many patients will 
meet several criteria.  
 
Note: eligibility clarifications settled by PI.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 11 of 56 
 
 
     Version 9.0   
5.1.3 Measurable disease defined as that which can be measured in at least one dimension (LD to be recorded) with a 
minimum size of 10 mm by CT scan 
 
5.1.4 ECOG 0-2 
 
5.1.5 Life expectancy of greater than 24 weeks. 
 
5.1.6  Age > 18 years. (There are no dosing or adverse event data currently available on the use of sunitinib in patients 
< 18 years of age, therefore patients in this age group are excluded from this study)  
 
5.1.7  Patients must have normal organ and marrow function 
 
5.1.8  Patients must have PT/INR/PTT within 1.2 X the upper limit 
 
5.1.9 Previous Therapy  
Radiation: Patients may have had prior radiation therapy. A minimum of 28 days must have elapsed between the end of 
radiotherapy and registration onto the study. Radiation must have involved < 30% of functioning bone marrow and 
there must be measurable disease outside the previously irradiated area (patients whose sole site of disease is in a 
previously irradiated area are ineligible UNLESS there is evidence of progression, or new lesions have been 
documented, in the irradiated field). Patients must have recovered from any acute toxic effects from radiation prior to 
registration. Previous Surgery: Previous major surgery is permitted provided that it has been at least 28 days prior to 
patient registration and that wound healing has occurred.  
 
5.1.10 Laboratory Requirements (must be done within 7 days prior to registration)  
Parameter 
Limit 
granulocytes (AGC) 
> 1.5 x 109/L 
platelets 
> 100 x 109/L 
bilirubin 
< 1.5xULN 
AST and ALT 
< 2.5 x ULN 
Amylase 
<1.5xULN 
Lipase 
<1.5xULN 
Calcium 
< 3 mmol/L 
creatinine  
< 2.0xULN  
 
 
5.1.11 Patient consent must be obtained according to local REB. The patient must sign the consent form prior to 
randomization or registration.  
 
5.1.12 Patients must be accessible for treatment, response assessment and follow-up. Investigators must assure 
themselves the patients registered on this trial will be available for complete documentation of the treatment, adverse 
events, and follow-up.  
 
5.1.13 Protocol treatment is to begin within 3 working days of patient registration.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 12 of 56 
 
 
     Version 9.0   
5.2  Exclusion Criteria 
 
5.2.1  History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ 
cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years or other 
malignancies associated with the same genetic syndrome. 
 
5.2.2 Patients with known brain metastases. (A head CT is not necessary to rule out brain metastases, unless there is 
clinical suspicion of CNS involvement). Patients with known brain metastases will be excluded from this trial due to 
their poor prognosis and their likelihood of developing progressive neurologic dysfunction that would confound the 
evaluation of neurologic and other adverse events.  
 
5.2.3 History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib.  
 
5.2.4 Patients receiving concurrent treatment with other anti-cancer therapy given for paraganglioma or 
pheochromocytoma or other therapy or other investigational anticancer agents.  
 
5.2.5 Patients who have received prior treatment with any other antiangiogenic agent or multi-targeted tyrosine kinase 
inhibitors (e.g., bevacizumab, sorafenib, pazopanib, thalidomide, AZD6474, AMG706, AZD2171, PTK787, VEGF 
Trap, etc.) are ineligible.  
 
5.2.6 Patients with any of the following cardiovascular findings are to be excluded:  
 
5.2.6.1 QTc prolongation (defined as a QTc interval equal to or greater than 500 msec) or other significant ECG 
abnormalities. An ECG must be done within 21days prior to registration and as clinically indicated.  
5.2.6.2 Current or history of Class III or IV heart failure as defined by the NYHA functional classification 
system (see Appendix V). 
5.2.6.3 Patients with prior anthracycline exposure, previous central thoracic radiation that included heart in 
radiation port, or a history of NYHA Class II cardiac function UNLESS  
 They are currently asymptomatic with respect to cardiac function AND  
 LVEF as assessed by MUGA at baseline is > lower limit of normal (LLN) of institution. The MUGA 
must be done within 21 days prior to registration.  
5.2.6.4 Poorly controlled hypertension (systolic blood pressure of 150 mmHg or higher or diastolic blood 
pressure of 90 mmHg or higher)  
5.2.6.5 Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, 
or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry  
5.2.6.6 History of venous thrombosis or pulmonary embolism in the past 3 months 
5.2.6.7 History of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to  
study entry  
 
5.2.7 Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin are 
excluded, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis. Note: Low molecular weight 
heparin is permitted provided the patient’s INR is < 1.5. INR must be done within 7 days prior to registration.  
 
5.2.8 Patients with bowel obstruction or any condition (e.g. gastrointestinal tract disease resulting in an inability to take 
oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic 
ulcer disease) that impairs their ability to swallow and retain sunitinib tablets.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 13 of 56 
 
 
     Version 9.0   
5.2.9 Patients with serious illness or medical condition which would not permit the patient to be managed according to 
the protocol including, but not limited to:  
• History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or l
 
imit compliance with study requirements  
• Active uncontrolled infection  
• Any other medical conditions that might be aggravated by treatment  
• Serious or non-healing wound, ulcer, or bone fracture.  
• Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment.  
 
5.2.10 Use of agents with proarrhythmic potential (amiodarone terfenadine, quinidine, procainamide, disopyramide, 
dofetilide, dronedarone, ibutilide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide) is not 
permitted during the study. A comprehensive list of agents with proarrhythmic potential can be found at 
http://crediblemeds.org.  
 
5.2.11 Because sunitinib is metabolized primarily by the CYP3A4 liver enzyme the concomitant use of certain drugs is 
prohibited. Patients receiving List A drugs below are not eligible unless > 7 days since last dose before starting 
sunitinib and no dosing during the trial. Patients receiving List B drugs below are not eligible unless > 12 days since 
last dose before starting sunitinib and no dosing during the trial. A comprehensive list of medications and substances 
known or with the potential to alter the pharmacokinetics of sunitinib through CYP3A4 is provided in Appendix VI.  
  
List A: Inhibitors/substrates – prohibited 7 days before dosing and during study.  
 azole antifungals (ketoconazole, itraconazole, miconazole, voriconazole)  
 Non-dihydropyridine calcium channel blockers: verapamil, diltiazem 
 Macrolide antibiotics: clarithromycin, erythromycin, telithromycin   
 HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir)  
 delavirdine  
 grapefruit juice 
 
List B: Inducers/substrates – prohibited 12 days before dosing and during study.  
 rifampin  
 Anti-convulsants: phenytoin, carbamazepine  
 rifabutin  
 St. John’s wort  
 efavirenz, nevirapine  
 Barbituates: phenobarbital  
 tipranavir  
 
5.2.12 Patients with pre-existing hypothyroidism prior to enrolment are ineligible unless they are euthyroid on 
medication.  
 
5.2.13 Because the effects of sunitinib on the developing human fetus and the newborn child at the recommended 
therapeutic dose are unknown, and because antiangiogenic agents are known to be teratogenic the following are 
exclusions for enrolment on the study:  
• Pregnant or lactating women. (N.B.: All women of childbearing potential must have a negative urine •-HCG 
pregnancy test within 7 days prior to registration).  
• Women of childbearing potential who do not agree to use adequate contraception (hormonal or barrier method 
of birth control; abstinence) prior to study entry and for the duration of study participation. (Should a woman become 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 14 of 56 
 
 
     Version 9.0   
pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician 
immediately).  
 
5.2.14 Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for 
pharmacokinetic interactions with sunitinib. In addition, these patients are at increased risk of lethal infections when 
treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination 
antiretroviral therapy when indicated.  
 
5.2.15 Greater than +1 proteinuria on urinary dipstick if also >1g urinary protein/24hrs 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 15 of 56 
 
 
     Version 9.0   
6.0 PRE-TREATMENT EVALUATION (all within 7 days of registration) 
 
History 
Physical Exam 
Endocrine Testing 
Demographics  
Height/weight  
24-hour urinary metanephrines 
Diagnosis of malignancy 
Vital signs 
24-hour urinary catecholamines 
Prior therapy  
ECOG performance status 
serum chromogranin A 
Concurrent illness 
Documentation of all measurable and 
non-measurable disease 
TSH, T4 
Concomitant medications 
Clinical tumour measurements (if 
applicable) within 7 days prior to 
registration 
 
NYHA functional status 
 
 
Baseline symptoms2 
 
 
 
 
 
Hematology 
Biochemistry 
Radiology (within 28 days) 
CBC + Differential  
BUN  
Chest Xray or chest CT scan 
PT/INR/PTT (if on coumadin or 
LMW heparin) 
Serum creatinine or calculated 
creatinine clearance1 (if serum 
creatinine > ULN) 
Abdominal and pelvic CT scan  
 
Sodium, potassium, chloride 
Clinical tumour measurements  
Other 
Bicarbonate 
 
urinalysis (dipstick for proteinuria) 
+/- 24 hr urine protein collect if 
>1+ on dipstick 
Bilirubin 
 
Urine pregnancy test (pre-
menopausal women of childbearing 
potential only) 
Alkaline phosphatase 
 
EKG to determine QTc3 
AST and ALT 
 
LVEF assessed by MUGA (for 
patients with class II NYHA, prior 
anthracyclines or central thoracic 
radiation, and at investigator’s 
discretion in patients without 
cardiac risk factors)3 
LDH 
 
Primary archival tissue block  
Total protein 
 
 
Calcium 
 
 
Phosphate 
 
 
Albumin 
 
 
Fasting glucose 
 
 
Amylase, lipase 
 
 
CPK 
 
1 Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula: GFR 
= 1.04 x (140-age) x weight in kg NB: this version of the formula incorporates a 15% reduction for women  
2 Adverse events will be recorded and graded using NCI Common Terminology Criteria for Adverse Events Version 
3.0 (CTCAE)  
3 EKG and LVEF assessed by MUGA within 21 days prior to registration 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 16 of 56 
 
 
     Version 9.0   
7.0 REGISTRATION PROCEDURES 
 
7.1 General Guidelines 
 
Following registration, patients should begin protocol treatment within 3 calendar days.  Issues that would cause 
treatment delays should be discussed with the Principal Investigator.  If a patient does not receive protocol therapy 
following registration, the patient’s registration on the study may be cancelled.  The Drug Development Program 
(DDP) Central Office Study Coordinator should be notified of cancellations as soon as possible. 
 
7.2 Registration Process 
 
Prior to registering a patient, each institution must have submitted all necessary regulatory documentation to the DDP 
Central Office Study Coordinator.  Case report form (CRF) information will only be sent once this has been received. 
 
No patient can receive protocol treatment until registration with the DDP Central Office has taken place.  All eligibility 
criteria must be met at the time of registration.  There will be no exceptions.  Any questions should be addressed with 
the Principal Investigator (cc the central office study coordinator). 
 
To register a patient, the following documents are to be completed by the research nurse or data manager and faxed to 
the DDP Study Coordinator: 
 Signed patient consent form 
 Eligibility Checklist signed by the investigator 
 
To complete the registration process, the DDP Study Coordinator will review the checklist and once eligibility has been 
confirmed: 
 Assign a patient study number 
 Register the patient on the study 
 Fax or e-mail the confirmation worksheet with the patient study number to the participating site 
 
To ensure immediate attention is given to the faxed checklist, each site is advised to also call the DDP Study 
Coordinator.  Patient registration will be accepted between the hours of 9am to 5pm Monday to Friday, excluding 
Canadian statutory holidays when the DDP Central Office will be closed. 
 
7.3 Initial Drug Ordering and Resupply 
 
Each participating institution will order sunitinib from the University Health Network – Princess Margaret Cancer 
Centre Pharmacy.  Investigational agents may be ordered by a participating site only after the initial REB approval for 
the site has been received and the site has been activated by the DDP Central Office.   
 
The participating site is responsible for requesting drug resupply by contacting the University Health Network – 
Princess Margaret Cancer Centre Pharmacy.  A minimum of 7 business days is required to process the request for 
resupply.   
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 17 of 56 
 
 
     Version 9.0   
8.0 TREATMENT PLAN  
 
8.1 Chemotherapy Treatment Plan  
7.1.1 Drug Administration  
Agent Dose Route Schedule sunitinib 50mg PO Daily once for 4 out of 6 weeks (1 cycle = 6 weeks) (4 weeks treatment 
plus 2 weeks observation). Sunitinib can be administered without regard to meals. Patients should be instructed to take 
their medication at approximately the same time every day. Doses should be recorded as appropriate on the CRF and 
patient diary.  
 
8.1.2 Premedications  
No routine premedications are advised but see section below for guidance of symptom management if required.  
 
8.1.3 Supportive Care  
The following are some general recommendations for management of sunitinib effects:  
 
Nausea/Vomiting 
Patients with treatment-related nausea should be treated initially with prochlorperazine – 10 mg every 8 hours orally as 
needed. If this is inadequate, a benzodiazepine such as lorazepam may be added until acute nausea is controlled or 
toxicity is limiting. Should this prove inadequate acutely, a steroid may be added in standard doses. Although QTc 
prolongation has not been seen in clinical trials, preclinical studies suggest sunitinib has the potential to prolong QTc. 
Therefore, since 5-HT3 antagonists have some effects on ECG intervals, 5-HT3 antagonists should be used with 
caution and patients should be monitored appropriately for any ECG changes or QTc prolongation. After acute nausea 
has resolved, consideration should be given to initiation of prophylactic antiemetic therapy. If nausea recurs despite 
reasonable medical intervention (as outlined above), dose reduction will be needed as described in Section 8.3.  
 
Diarrhoea 
Diarrhoea should be managed with loperamide: 4 mg at first onset, then 2 mg every 2-4 hours until diarrhoea is 
controlled (maximum = 16 mg loperamide per day).  
  
Hand-foot Syndrome  
Hand-foot syndrome may be treated with topical emollients, topical or systemic steroids, and/or antihistamine agents as 
needed. Vitamin B6 (pyridoxine; 50-150 mg orally each day) may also be used.  
 
Complications of Myelosuppression:  
Neutropenic fever or infection with neutropenia should be evaluated promptly and treated with antibiotic therapy 
with/without therapeutic colony-stimulating factors according to local guidelines. Transfusion support should be 
administered as clinically indicated. Erythropoietic agents may be used at the discretion of the treating physician 
according to local guidelines.  
 
8.2 Patient Monitoring  
 
Blood pressure  
Patients should have blood pressure determined weekly for the first cycle of therapy and then at least every two weeks 
thereafter (see Appendix VII). More frequent blood pressure assessment will be required should hypertension be 
documented: BP should be repeated daily if BP rises to >150/100 if previously normal or if there is a recurrent 
persistent (>24 h) increase of >20 mmHg. Management is outlined in section 7.3. Blood pressure data should be 
recorded as appropriate on the CRFs.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 18 of 56 
 
 
     Version 9.0   
Cardiac monitoring 
Patients with prior anthracycline exposure, previous central thoracic radiation that included heart in radiation port, or a 
history of NYHA Class II cardiac function should be routinely monitored for changes in LVEF (see section 9.0). 
Patients should be carefully monitored for clinical signs and symptoms of cardiac failure while receiving sunitinib. 
Cardiac monitoring of patients without cardiac risk factors should be done at the investigator’s discretion.  
 
Tumour lysis 
Patients with bulky solid tumors should be monitored closely for pneumothorax, intestinal fistulae, and intestinal 
perforation in the event of rapid tumor destruction. This may be seen early in treatment. Tumour-related hemorrhage 
can be seen in conjunction with tumour degeneration and can be a possible life-threatening event.  
 
Abdominal tumour degeneration 
Serious complications of degeneration or shrinkage of abdominal tumours attached to the bowel wall, including GI 
perforation, have occurred in patients taking sunitinib. This may happen early in treatment. Tumour related hemorrhage 
can occur in conjunction with tumour degeneration and can be a possible life-threatening event.  
 
Hypothyroidism 
Patients taking sunitinib can experience a decrease in thyroid function. Patients should be followed closely for the signs 
of symptoms of hypothyroidism and thyroid hormone replacement should be initiated as appropriate.  
 
Adrenal gland insufficiency 
Although adrenal gland insufficiency is rarely seen with sunitinib treatment, patients should be clinically followed for 
the signs and symptoms of this complication, especially (1) patients with comorbidities associated with adrenal 
dysfunction, (2) patients with pre-existing adrenal insufficiency (primary or secondary), and (3) patients with 
concomitant stress (e.g., fever, infection, bleeding, serious accident, surgery) that may precipitate overt adrenal 
insufficiency in the presence of subclinical sunitinib-induced adrenal toxicity. If clinically indicated, objective testing 
for adrenal gland function should be conducted.  
 
Skin discoloration 
Patients should be alerted to the possibility that sunitinib capsules can cause a yellow discoloration of the skin on direct 
contact. If this happens, the patient should wash immediately with soap and water.  
 
Patient Drug Administration 
Patients will be provided with a diary for recording the date and exact time that each dose of sunitinib is taken. Patients 
will be asked to return the diary to the study nurse at each physician’s visit, at the end of each cycle.  
 
Liver Function 
Hepatic impairment and/or failure, have been reported with the use of sunitinib. Patient’s liver function tests will be 
assessed as nonclinically significant before entry into trial, and will be monitored throughout.   
 
8.3 Dose Adjustments  
 
Doses will be reduced for hematologic and other adverse events. Dose adjustments are to be made according to the 
system showing the greatest degree of toxicity. Adverse events will be graded using the NCI Common Terminology 
Criteria for Adverse Events Version 3.0 (CTCAE) (see Appendix IV). 
 
  
 
 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 19 of 56 
 
 
     Version 9.0   
Sunitinib dose levels* 
Dose Level 
Daily Dose 
-3 
12.5 mg 
 
-2 
25 mg 
  
-1 
37.5 mg 
 
0 
50 mg 
 
 
* dispensed using 12.5mg, 25mg and 50mg capsules as applicable 
 
 
The major toxic effects of sunitinib which may limit dose are: neutropenia, thrombocytopenia, fatigue, hand-foot 
syndrome, hypertension, and changes in liver enzymes. The guidelines that follow outline dose adjustments for several 
of these toxic effects. If a patient experiences several adverse events and there are conflicting recommendations, please 
use the recommended dose adjustment that reduces the dose to the lowest level.  
 
For all dose modifications, please note:  
 
• Cycle length of 6 weeks should be maintained even if doses are missed during the 4 weeks of planned treatment (i.e. 
treatment interruptions should not re-set the cycle timing such that the next cycle starts earlier and missed doses should 
not be ‘made up’ in the observation period during weeks 5 and 6). However, the cycle length may be increased in the 
event that a new cycle of treatment is delayed.  
• Supportive care recommendations for sunitinib-related effects can be found in section 8.1.3.  
• Patients requiring more than three dose reductions will be removed from protocol therapy.  
• Patients who do not recover from toxic effects as required within 3 weeks will be removed from protocol therapy.  
• No dose escalations are permitted after reductions for confirmed toxicity (except for the circumstance as described for 
QTc prolongation in section 8.3).  
 
8.3.1 Non-Hematologic Adverse Events Related to Sunitinib  
 
Hypertension Management  
Specific guidelines for management of this adverse event are provided in the table below. In addition, guidance on the 
collection and recording of BP information is provided in Appendix VII.  
 
 
BP measurements – 
systolic/diastolic 
 
Treatment/Dose Modification 
Patients not receiving maximal antihypertensive therapy: 
140-149 mmHg (systolic) 
OR 
90-99 mmHg (diastolic) 
 
 
Add new or additional antihypertensive meds or increase dose of 
existing meds 
 
Maintain dose of sunitinib 
150-179 mmHg (systolic) 
OR 
 
Add new or additional antihypertensive meds or increase dose of 
existing meds 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 20 of 56 
 
 
     Version 9.0   
100-104 mmHg (diastolic) 
 
 
Hold sunitinib until BP falls to <140/90 
 
Decrease sunitinib by 1 dose level if 2 new antihypertensive drugs 
added to control BP 
> 180 mmHg (systolic) 
OR 
> 105 mmHg (diastolic) 
 
Hold sunitinib until BP controlled 
 
Add new or additional antihypertensive meds or increase dose of 
existing meds 
 
Monitor patient closely for hypotension (if on antihypertensive 
meds) until sunitinib is restarted. 
 
Resume sunitinib at the next lower dose level when BP falls to 
<140/90 
Hypertensive Crisis 
 
Discontinue sunitinib; Take off study  
 
Hospitalize patient for management 
Patients receiving maximal antihypertensive therapy (four antihypertensives for 2 weeks without dose 
modification of antihypertensive medications):  diuretics, beta blocker or central sympathetic blocker, 
ACE inhibitor or ARB and vasodilator or calcium channel blocker (CCB) 
> 160 mmHg (systolic) 
OR 
> 105 mmHg (diastolic) 
 
Hold sunitinib 
 
Maintain antihypertensive meds and monitor patient closely for 
hypotension until sunitinib is restarted. 
 
Resume treatment at one lower dose level when BP falls to 
<140/90 
Hypertensive Crisis 
 
Discontinue sunitinib; Take off study  
 
Hospitalize patient for management 
* 
Maximal antihypertensive therapy is defined as four antihypertensive medications given for 2 
weeks. 
 
Oral antihypertensive medications 
Agent  
class 
 
Agent 
Initial 
dose 
Intermediate 
dose 
Maximum 
dose 
Hepatic 
metabolism 
Dihydro-
pyridine 
Calcium-
Channel 
Blockers 
(DHP CCB) 
nifedipine XL 
30 mg daily 
60 mg daily 
90 mg daily 
CYP 3A4 
substrate 
amlodipine 
2.5 mg daily 
5 mg daily 
10 mg daily 
CYP 3A4 
substrate 
felodipine 
2.5 mg daily 
5 mg daily 
10 mg daily 
CYP 3A4 substrate 
and inhibitor 
Selective 
 Blockers 
(BB) 
metoprolol 
25 mg  
twice daily 
50 mg 
twice daily 
100 mg  
twice daily 
CYP 2D6 substrate 
atenolol 
25 mg daily 
50 mg daily 
100 mg daily 
No 
acebutolol 
100 mg  
twice daily 
200-300 mg 
twice daily 
400 mg  
twice daily 
Yes (CYP450 
unknown) 
bisoprolol 
2.5 mg daily 
5-10 mg daily 
20 mg daily 
Yes (CYP450 
unknown) 
Angiotensin 
Converting 
Enzyme 
captopril 
12.5 mg 3x 
daily 
25 mg 3x daily 
50 mg 3x daily 
CYP 2D6 substrate 
enalapril 
5 mg daily 
10-20 mg daily 
40 mg daily 
CYP 3A4 substrate 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 21 of 56 
 
 
     Version 9.0   
Inhibitors 
(ACEIs) 
 
ramipril 
2.5 mg daily 
5 mg daily 
10 mg daily 
Yes (CYP450 
unknown) 
lisinopril 
5 mg daily 
10-20 mg daily 
40 mg daily 
No 
fosinopril 
10 mg daily 
20 mg daily 
40 mg daily 
Yes (CYP450 
unknown) 
Rarely used:       
perindopril 
 
4 mg daily 
 
none 
 
8 mg daily 
 
Yes, but not 
CYP450 
Rarely used:       
quinapril 
10 mg daily 
20 mg daily 
40 mg daily 
No 
Angiotensin II 
Receptor 
Blockers 
(ARBs) 
losartan 
25 mg daily 
50 mg daily 
100 mg daily 
CYP 3A4 substrate 
candesartan 
4 mg daily 
8-16 mg daily 
32 mg daily 
CYP 2C9 substrate 
irbesartan 
75 mg daily 
150 mg daily 
300 mg daily 
CYP 2C9 substrate 
telmisartan 
40 mg daily 
none 
80 mg daily 
Yes, but not 
CYP450 
valsartan 
80 mg daily 
none 
160 mg daily 
Yes, but not 
CYP450 
 and   
Blocker 
labetolol 
100 mg twice 
daily 
200 mg twice 
daily 
400 mg twice 
daily 
CYP 2D6 substrate 
and inhibitor 
Agents in bold characters are suggested as optimal choices to avoid or minimize potential drug-interactions with 
sunitinib through CYP450 
8.3.2Management of Paroxysmal Hypertension 
 
All patients must have adequate blood pressure control before entry into the trial. This includes persistent hypertension 
as well as episodic paroxysmal hypertension. If the patient experiences paroxysmal hypertension or symptoms thereof 
during the trial, the patient will cease sunitinib until blood pressure is controlled. The investigators will then ensure that 
the patient has not progressed. Subsequently, management will be as follows; 
 
1) Gradual titration with a calcium entry blocker (Norvasc) (amlodipine) starting with 5 mg/day for a total of 20 
mg/day. The aim will be to keep BP at less than 150/90 mm. 
 
If the above alone is insufficient at maximal doses, consideration will be given to the addition of one of the following 
agents: 
 
2) The mixed alpha/beta receptor blocker labetolol at 200 mg twice daily up to a maximum of 400 mg twice daily.  
 
3) The alpha 1 receptor blocker doxazosin (Prazosin) 2 mg up to a maximum of 16 mg/day will be considered for 
refractory cases. 
 
Should the patient’s blood pressure fail to be controlled by these measures, or whose overall condition deteriorates due 
to uncontrolled hypertension will be discontinued from the protocol and treated with ongoing best supportive care.  
 
 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 22 of 56 
 
 
     Version 9.0   
8.3.3 Hematological toxicity 
 
The following table outlines when dose adjustments are required for haematological toxicity  
 
 
Event 
AE Grade 
or 
Observation 
Dose modification 
Neutropenia† 
Grades 1 and 2 
Maintain dose 
Grade 3 * ‡ 
Hold sunitinib until < grade 2, then resume at same 
dose level 
Grade 4 * 
Hold sunitinib until < grade 2, then reduce 1 dose 
level and resume treatment 
Thrombocytopenia† 
Grades 1 and 2 
Maintain dose 
Grade 3 * ‡ 
Hold sunitinib until < grade 2, then resume at same 
dose level 
Grade 4 * 
Hold sunitinib until < grade 2, then reduce 1 dose 
level and resume treatment 
† Must be documented on 2 separate occasions at least 24 hours apart. 
 * If neutrophil and/or platelet counts have not recovered to baseline or better within 3 weeks of dose interruption, the 
patient is withdrawn from the study ‡ Recurrent grade 3 events require dose reduction. 
 
 
8.3.4 Other Non-Hematologic Adverse Events  
 
 
Event 
AE Grade 
or 
Observation 
Dose modification 
Fever, chills, flu-like 
symptoms 
Grades 1-4 
Maintain dose 
Fatigue (lethargy, 
malaise, asthenia) 
Grades 1 and 2 
Maintain dose 
Grade 3 * 
Hold sunitinib until < grade 2, then reduce 1 dose 
level and resume treatment 
Grade 4 
Hold sunitinib until < grade 2, then reduce 1 dose 
level and resume treatment 
 
 
 
 
>450 but 
 < 550 msec 
 
Review patient’s concomitant medications for 
QT interval-prolonging agents.  Correct any 
electrolyte abnormalities. 
 
Continue sunitinib at current dose level. 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 23 of 56 
 
 
     Version 9.0   
 
 
 
QTc Prolongation 
> 550 msec 
 Stop sunitinib and any other QT-interval 
prolonging agents immediately.  Correct any 
electrolyte abnormalities , then 
1. If there is a plausible explanation for AE 
other than sunitinib treatment, resume 
sunitinib at current dose level. 
2. If sunitinib may have contributed to the AE: 
 
Reduce 2 dose levels and restart 
sunitinib. 
 
If QTc remains <500 msec after 14 
days at reduced dose, increase one dose 
level and continue sunitinib. 
If QTc remains <500 msec after 14 days, original 
dose of sunitinib may be resumed. 
Hand-foot syndrome 
Grades 1 and 2 
Maintain dose 
Grade 3 * 
Hold sunitinib until < grade 1, then resume 
treatment at same dose or reduce 1 dose level 
Grade 4 
Hold sunitinib until < grade 1, then reduce 1 dose 
level or discontinue treatment 
AST and/or ALT 
elevation 
(SGOT, SGPT) 
Grades 1-2 
Maintain dose * 
Grades 3-4 
Sunitinib held until <grade 2,then resume at dose 
level-1. If grade 3-4 recurs a 2nd time, discontinue 
sunitinib. Also discontinued if there is no resolution 
to < grade 2 on first episode.     
Posterior Reversible 
Encephalopathy 
Syndrome 
Any occurrence 
Cease sunitinib and await recovery with 
symptomatic management.  Discontinue treatment. 
CPK elevation 
Grade 2 
Hold sunitinib until < grade 2, then reduce 1 dose 
level and resume treatment 
 
* 
Recurrent grade 3 events require dose reduction. 
 
• Patients requiring a delay of > 4 weeks or > 3 dose reductions should go off protocol therapy but may remain at the 
principal investigators discretion 
• 24-48 hrs are suggested as elapse time between decision steps suggested in the algorithm unless persistent severe 
hypertension occurred.  
• Hypertension should be graded according to NCI CTCAE Version 3.0 and recorded on CRFs.  
• While patients are receiving treatment with sunitinib, the early initiation of antihypertensive treatment for grade 1 or 2 
hypertension to minimize more severe or persistent hypertension is not considered a grade 3 adverse event.  
• Decisions to hold or decrease the sunitinib dose during treatment must be based on BP readings taken in the clinic by 
a medical professional.   
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 24 of 56 
 
 
     Version 9.0   
LVEF dose modification  
 
Asymptomatic Decrease in LVEF  
The decision to continue or hold STUDY DRUG is based on the ejection fraction as it relates to the institution’s LLN 
and change in ejection fraction from screening (LVEF as measured at registration) according to the following table:  
 
 
Discontinue sunitinib if:  
• after holding study drug for 2 weeks, the repeat MUGA has not improved to normal or to the levels  
that allow continuing treatment  
• after holding study drug, and restarting it, the LVEF falls again into the “hold” range IF LVEF remains at a “Continue 
And repeat MUGA” or improves from a HOLD to a “Continue And repeat MUGA” category, additional MUGA scans 
prior to the next scheduled MUGA will be at the discretion of the investigator.  
 
Symptomatic Cardiac Events  
Discontinue sunitinib if:  
• Patient has symptoms of CHF and a diagnosis of CHF is confirmed  
• Patient has a myocardial infarction  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 25 of 56 
 
 
     Version 9.0   
8.3.5 Other Hematologic and Non-hematologic Adverse Events (not specifically addressed above)  
 
General Management Guidelines 
Observation 
Action 
AE resolves promptly* with supportive care 
Maintain dose level 
1. Grade 3 or higher (non-haematological) AE 
related to sunitinib and lasting >5 days that 
does not resolve to grade 2 or below despite 
maximum supportive care for < 48 hours. 
 
2. Lower grade but related AEs (e.g., creatinine) 
 
 
 
Reduce one dose level 
AE does not resolve to grade 2 or below after 
treating patient at the lowest (i.e., 25 mg daily) 
reduced dose level. 
In general, remove patient 
from study  
 
*Prompt resolution indicates resolution to grade 2 or below. 
 
8.4 Concomitant Therapy  
 
8.4.1 Permitted  
Patients may receive ongoing supportive and palliative care (eg. pain control) as clinically indicated throughout the 
study. All supportive medications must be recorded on the case report form (CRF) as appropriate.  
 
8.4.2 Not permitted  
The case report form (CRF) must capture the concurrent use of all other drugs, over-the-counter medications, or 
alternative therapies including herbal supplements, specifically, St. John’s wort (which is not permitted). The Principal 
Investigator should be alerted if the patient is taking any agent known to affect or with the potential to affect selected 
P450 isoenzymes. (A comprehensive list of CYP3A4-interactive agents is provided in Appendix VI.) If any of the 
prohibited concomitant medications become necessary for patient management, please contact the pharmacy for 
discussion about appropriate washout periods and possible drug interactions.  
 
Cytochrome P450 inhibitors, substrates or inducers:  
 
• Sunitinib is primarily metabolized by liver enzymes, particularly CYP3A4. Co-administration of potent inhibitors or 
inducers of this enzyme can result in significant changes in exposure to sunitinib (e.g., a mean 1.8-fold increased 
exposure with ketoconazole and a mean 4-fold decrease with rifampin). For this reason, use of the following agents is 
not permitted before or during the study:  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 26 of 56 
 
 
     Version 9.0   
 
Inhibitors/substrates – prohibited 7 days before 
dosing and during study 
Inducers/substrates – prohibited 12 days before 
dosing and during study.  
 
azole antifungals (ketoconazole, itraconazole, 
miconazole, voriconazole)  
 
rifampin 
HIV protease inhibitors (indinavir, saquinavir, 
ritonavir, atazanavir, nelfinavir)  
 
Anti-convulsants: carbamazepine, phenytoin  
 
Macrolide Antibiotics: clarithromycin, erythromycin, 
telithromycin 
rifabutin 
Non-dihydropyridine calcium channel blockers: 
diltiazem verapamil  
 
 
 
St. John’s wort  
 
delavirdine  
 
 
 
HIV antivirals: efavirenz, nevirapine 
grapefruit juice 
phenobarbital 
 
tipranavir  
 
A comprehensive list of CYP3A4 inhibitors, inducers, and substrates is provided in Appendix VI.  
 
Steroids:  
• Steroid use is not recommended during sunitinib treatment unless absolutely necessary (e.g., for treatment of adverse 
events or protocol-required premedication) because many steroids (e.g., prednisone, prednisolone, dexamethasone, etc) 
effectively lower sunitinib exposure through CYP3A4 interactions.  
 
Anticoagulants:  
• The use of coumadin-derivative anticoagulants such as warfarin (Coumadin®) in therapeutic doses is not permitted, 
although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis. Low molecular weight heparin is 
permitted provided the patient’s INR is < 1.5.  
 
Dysrythmic drugs:  
• Use of agents with proarrhythmic potential (amiodarone, terfenadine, quinidine, procainamide, disopyramide, 
dofetilide, dronedarone, ibutilide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, and flecainide) is 
not permitted during the study. A comprehensive list of agents with proarrhythmic potential can be found at 
http://crediblemeds.org.  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 27 of 56 
 
 
     Version 9.0   
9.0 EVALUATION DURING AND AFTER PROTOCOL TREATMENT 
9.1 Evaluation During Protocol Treatment  
Investigation 
Timing 
Investigation 
Timing 
History and Physical 
Exam 
Day 1 each cycle10,11 
CBC, differential 
Day 1 each cycle (prior 
to treatment)7,11  
 
Weight, performance 
status8 
Day 110,11, 15, and 29 each 
cycle 
PT/INR/PTT 2 
Twice weekly for first 3 
weeks, then as clinically 
indicated 
Clinical tumour 
measurements 
End of every even numbered 
cycles 
Biochemistry 
Day 1 each cycle7,11 
 
Blood pressure, heart 
rate9  
Weekly for cycle 110 then 
Day 111, 15, and 29 each 
cycle thereafter (assessed by 
nurse or home monitor) 
BUN, serum 
creatinine/clearance3, 
sodium, potassium, 
chloride, bicarbonate, 
bilirubin, alkaline 
phosphatase, AST,  
ALT, LDH, total 
protein, calcium, 
phosphate, albumin, 
glucose, CPK 
Day 1 each cycle7,11 
Adverse Events/ Toxicity 
Evaluation5 
Each visit at the end of 
every cycle 
Amylase, Lipase 
Day 1 each cycle7,11 
Urinalysis 
Day 1 each cycle7,11 
TSH, T4 
Day 1 each cycle7,11 
EKG 
Day 1 of even numbered 
cycles11 
LVEF4,6/ MUGA 
Day 1 of even numbered 
cycles11 
Endocrine testing 
(urinary metanephrines, 
catecholamines and 
serum chromogranin A)  
Day 1, every 2 cycles11 
CXR or CT4,12  
End of even numbered 
cycles 
Each visit: 
1 Repeat daily if BP > 150/100 mmHg if previously WNL, OR recurrent, persistent (> 24Hrs) or symptomatic increase by > 20 
mmHg and manage as per Section 8.3.  
2 Only for patients receiving low dose anticoagulants (< 2 mg coumadin, warfarin) or LMW heparin.  
3 Only required if serum creatinine is > ULN. Creatinine clearance to be measured directly by 24 hour urine sampling or as 
calculated by Cockcroft Formula: GFR = 1.04 x (140-age) x weight in kg NB: this version of the formula incorporates a 15% 
reduction for women  
4 To ensure comparability, baseline xrays/scans/LVEF and subsequent xrays/scans/LVEF to assess response and cardiac effects 
must be performed using identical techniques.  
5 Adverse events will be recorded and graded using NCI Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) 
(Appendix IV)  
6 LVEF required in patients with class II NYHA, prior anthracyclines or prior central thoracic radiation, and at investigator’s 
discretion in patients without cardiac risk factors. Identical technique must be used throughout.  
7 Excluding cycle 1 
8 Can be once per cycle at physician’s discretion for cycle 3+ 
9 Weekly for cycle 1 then day 1, 15, 29 for cycle 2-3, then can be once per cycle at physician’s discretion. Repeat daily if BP > 
150/100mm HG if previously within normal limits, or recurrent, persistent (>24 hrs) or symptomatic increase > 20 mm Hg and 
manage as per protocol. Measurements may be performed more frequently at physician’s discretion. 
10 Measurements do not have to be repeated cycle 1 Day 1, if screening visit occurred ≤ 3 days prior.  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 28 of 56 
 
 
     Version 9.0   
11 Day 1 assessments must be within 7 days prior to cycle day 1. 
12At investigator discretion, frequency of CT imaging can be decreased from every 12 weeks to every 4 months  (+/- 2 weeks) for 
 patients receiving ongoing study treatment with responding or stable disease. 
 
9.2 Evaluation After Protocol Treatment  
All patients will be seen at 4 weeks after completion of protocol therapy.  
 
For patients who go off protocol treatment with progressive disease (PD), follow-up will be required every 3 months to 
document ongoing toxicities related to protocol treatment (until resolved to < grade 2), late toxicities (including second 
malignancies), and death.  
 
For patients who go off protocol treatment with CR, PR, or SD ongoing, follow-up will be required every 3 months to 
document relapse/progression, ongoing toxicities related to protocol treatment (until resolved to < grade 2), late 
toxicities (including second malignancies), and death (see Appendix I for investigations to be performed).  
 
10  CRITERIA FOR MEASUREMENT OF STUDY ENDPOINTS  
 
10.1 Definitions  
 
10.1.1  
Evaluable for toxicity. All patients will be evaluable for toxicity from the time of their first treatment with sunitinib.  
 
10.1.2  
Evaluable for response. All patients who have received at least two cycles of therapy and have their disease re-
evaluated will be considered evaluable for response (exceptions will be those who exhibit objective disease progression 
prior to the end of cycle 1 who will also be considered evaluable). Patients on therapy for at least this period and who 
meet the other listed criteria will have their response classified according to the definitions set out below (Eisenhauer E, 
2009).  
 
10.2 Response and Evaluation Endpoints  
 
Response and progression will be evaluated in this study using the international criteria proposed by the RECIST 
(Response Evaluation Criteria in Solid Tumors) committee version 1.1 (Eisenhauer E, 2009).  
 
10.2.1 Measurable Disease. 
Measurable tumour lesions are defined as those that can be accurately measured in at least one dimension (longest 
diameter to be recorded) with a minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm), 10 mm 
caliper measurement by clinical exam or 20 mm by chest X-ray.  Malignant lymph nodes considered to be 
pathologically enlarged and measurable, must be  15 mm in short axis when assessed by CT scan.  
 
10.2.2 Non-measurable Disease.  
All other lesions (or sites of disease), including small lesions (longest diameter < 10 mm or pathological lymph nodes 
with  10 to < 15 mm short axis) as well as truly non-measurable lesions.  Lesions considered truly non-measurable 
include: leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitic involvement of skin or lung, 
inflammatory breast disease, abdominal masses/abdominal organomegaly identified by physical exam that is not 
measurable by reproducible imaging techniques. 
 
10.2.3 Target Lesions.  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 29 of 56 
 
 
     Version 9.0   
All lesions up to a maximum of 5 lesions total (and a maximum of two lesions per organ) representative of all involved 
organs should be identified as target lesions and will be recorded and measured at baseline. Target lesions should be 
selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in 
addition should lend themselves to reproducible repeated measurements.  Pathological nodes, which are defined as 
measurable and may be identified as target lesions if the short axis is  15 mm by CT scan.  A sum of the diameters 
(longest for non-nodal lesions, short axis for nodal lesions) will be calculated and reported as the baseline sum 
diameters. If lymph nodes are included in the sum, only the short axis is added into the sum.  The baseline sum 
diameters will be used as reference to further characterize any objective tumour regression in the measurable dimension 
of the disease.  
 
10.2.4 Non-target Lesions.  
All other lesions (or sites of disease) including pathological lymph nodes should be identified as non-target lesions and 
should also be recorded at baseline.  Measurements are not required but these lesions should be noted at baseline and 
should be followed as “present”, “absent” or in rare cases “unequivocal progression”.   
 
10.2.5 RESPONSE  
All patients will have their BEST RESPONSE on study classified as outlined below:  
 
Complete Response (CR): disappearance of all target lesions.  Pathological lymph nodes (whether target or non-target) 
must have reduction in short axis to < 10 mm. 
 
Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline 
sum diameters.  
 
Stable Disease (SD): steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.  
 
Progressive Disease (PD): at least   20% increase in the sum of diameters of target lesions taking as reference the 
smallest sum on study (includes baseline sum if that is smallest on study). In addition, the sum must also demonstrate 
an absolute increase of at least 5 mm.  Appearance of new lesions will also constitute progressive disease. In 
exceptional circumstances, unequivocal progression of non-target lesions may be accepted as evidence of disease 
progression.  
 
 
 
Response Criteria  
Target 
Lesions 
Non-Target 
Lesions 
New 
Lesions 
Overall 
Response 
CR 
CR 
No 
CR 
CR 
Non-CR/Non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all 
evaluated 
No 
PR 
SD 
Non-PD or not all 
evaluated 
No 
SD 
Not all 
evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD* 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
* 
In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as 
disease progression. 
 
Note: Patients with a global deterioration of health status requiring discontinuation of treatment 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 30 of 56 
 
 
     Version 9.0   
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration”.  Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 31 of 56 
 
 
     Version 9.0   
10.3 Response Duration  
Response duration will be measured from the time measurement criteria for CR/PR (whichever is first recorded) are 
first met until the first date that recurrent or progressive disease is objectively documented, taking as reference the 
smallest measurements recorded on study.  
 
10.4 Stable Disease Duration  
Stable disease duration will be measured from the time of start of therapy until the criteria for progression are met, 
taking as reference the smallest sum on study.  
 
10.5 Methods of Measurement  
The same method of assessment and the same technique should be used to characterize each identified and reported 
lesion at baseline and during follow-up.  
 
10.5.1 Clinical Lesions. Clinical lesions will only be considered measurable when they are superficial and  10 
mm diameter as assessed using calipers (e.g. skin nodules). For the case of skin lesions, documentation by colour 
photography including a ruler to estimate the size of the lesion is recommended.  When lesions can be evaluated by 
both clinical exam and imaging, imaging evaluation should be undertaken since it is more objective and may also be 
reviewed at the end of the study. 
 
10.5.2 Chest X-ray. Lesions on chest X-ray are acceptable as measurable lesions when they are clearly defined 
and surrounded by aerated lung. However, CT is preferable.  
 
10.5.3 CT, MRI. CT is the best currently available and reproducible method to measure lesions selected for 
response assessment. CT should be performed with slice thickness of 5 mm or less.  When CT scans have slice 
thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is also 
acceptable in certain situations (e.g. for body scans). 
 
10.5.4 Ultrasound. Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement.  Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date 
and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be 
taken from one assessment to the next.  If new lesions are identified by ultrasound in the course of the study, 
confirmation by CT or MRI is advised.   
 
10.5.5 Endoscopy, Laparoscopy. The utilization of these techniques for objective tumour evaluation is not 
advised.  However, such techniques can be useful to confirm complete pathological response when biopsies are 
obtained or to determine relapse in trials where recurrence following complete response or surgical resection is an 
endpoint.  
 
10.5.6 Cytology, Histology. These techniques can be used to differentiate between PR and CR in rare cases  
(for example, residual lesions in tumour types such as germ cell tumours, where known residual benign tumours can 
remain). The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment 
can be considered if the measurable tumour has met criteria for response or stable disease in order to differentiate 
between response (or stable disease) and progressive disease.  
 
 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 32 of 56 
 
 
     Version 9.0   
10.6 Endocrine Response  
24-hour urinary metanephrines, catecholamines and serum chromogranin A will be measured after the end of each 12 
week cycle (ie. end of every two cycles). Subjects will be considered evaluable for endocrine response if they have 
completed at least one full cycle of treatment. An endocrine response will be as defined by a > 20% drop in one of the 
aforementioned parameters and sustained for >12-week period and will be considered a secondary endpoint of the trial. 
  
11.0 STATISTICAL CONSIDERATIONS  
 
11.1 Objectives and Design  
This is a phase II study to investigate the efficacy of sunitinib in patients with advanced paraganglioma/ 
pheochromocytoma. The protocol will accrue up to 28 response evaluable patients. In order to minimize the expected 
number of patients treated in the event that the regimen proves to be very disappointing or very successful, a multi-
stage design will be used for each cohort for patient accrual (Fleming T 1982).  
 
11.2 Primary Endpoints and Analysis  
The primary end point will be clinical benefit rate (CBR) which will be defined as either a partial response (PR) 
complete response (CR) or stable disease (SD) for ≥ 12 weeks. This will be measured using the Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria. 
.  
The secondary end points will be as follows: 
1. Biochemical response as defined by a > 20% drop in one of; 24-hour urinary metanephrines, catecholamines or 
serum chromogranin A, and sustained for >12-week period 
2. Overall survival 
3. Time to progression 
4. Overall response rate (PR) + (CR) 
5. tumour symptom improvement (descriptive) 
 
NB: Response is defined as per the RECIST criteria as a 30% decrease in the sum of the diameters of the target lesions 
(partial response) maintained for at least 4 weeks, or complete disappearance of disease and cancer related symptoms 
(complete response), also maintained for at least 4 weeks. The 95% confidence interval for response rate will be 
calculated. The median and range of the duration of response will be assessed.  
 
11.3 Sample Size and Duration of Study  
 
Stage 1 of accrual: 14 response evaluable patients will be entered in the first stage. Using response hypotheses 
of H0 < 5 % and Ha> 20%, we would reject the drug at the end of the first stage of accrual no response was seen. 
Otherwise, additional 14 patients will be accrued to the cohort.  
 
Stage 2 of accrual: Additional 14 patients will be accrued. We would accept the drug as active if three or more 
responses (as defined by the CBR) are observed from 28 patients accrued.  
 
Significance level and power: The procedure described above test the null hypothesis that the response rate is 
5% versus alternating hypotheses that the response rate is 20%. The significance level (i.e., the probability of rejecting  
H0 when it is true) is =0.14 and the power (i.e., the probability of deciding the regimen is active) is 0.92 when true 
response rate is 20%. The expected sample size with this design is 28. 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 33 of 56 
 
 
     Version 9.0   
Accrual and duration of study  
The estimated monthly accrual for this study is 1-2 patients a month. Thus, patient accrual is expected to be completed 
within 12-48 months. Additional time is required to allow the response data to mature.   
 
12.0 PROTOCOL TREATMENT DISCONTINUATION AND THERAPY AFTER STOPPING  
 
12.1 Criteria for Discontinuing Protocol Treatment  
Patients may stop protocol treatment in the following instances:  
• Intercurrent illness which would, in the judgement of the investigator, affect assessments of clinical status to a 
significant degree, and require discontinuation of protocol therapy.  
• Unacceptable toxicity as defined in section 8.  
• Tumour progression or disease recurrence as defined in section 10.  
• Request by the patient.  
• Completion of therapy as outlined below in section 12.2  
Efforts should be made to maintain the investigations schedule and continue follow-up, even if patients discontinue 
protocol treatment prematurely and/or no longer attend the participating institution.  
 
12.2 Duration of Protocol Treatment  
(see section 10 for response definition)  
• For complete responders, therapy will continue until progression or for 2 cycles after CR criteria are first met.  
• For partial responders, therapy will continue until progression or for 2 cycles after documentation of stable partial 
response (i.e. no further tumour shrinkage documented).  
• For stable patients, therapy will continue for a maximum of 6 cycles but at the investigator's discretion. Patients who 
have no evidence of response at this point should go off therapy and receive other treatment at the investigator's 
discretion.  
• Patients who progress (treatment failure) will go off study at the time progression is documented clinically and/or 
radiographically. 
 
12.3 Therapy After Protocol Treatment is Stopped  
At the discretion of the investigator.  
 
12.4  Follow-up Off Protocol Treatment  
All patients will be seen at 4 weeks after completion of protocol therapy.  
 
For patients who go off protocol treatment with progressive disease (PD), follow-up will be required every 3 months to 
document ongoing toxicities related to protocol treatment (until resolved to < grade 2), late toxicities (including second 
malignancies), and death.  
 
For patients who go off protocol treatment with CR, PR, or SD ongoing, follow-up will be required every 3 months to 
document relapse/progression, ongoing toxicities related to protocol treatment (until resolved to < grade 2), late 
toxicities (including second malignancies), and death (see Appendix I for investigations to be performed).  
 
13 TRANSLATIONAL RESEARCH 
Given our hypothesis that it is the pseudo-hypoxic drive that leads to tumour progression, archival specimen markers 
may have both prognostic and predictive value in this setting.  Primary archival tumor tissue block will be obtained 
from each patient so that VHL, RET and succinate dehydrogenase mutations will be analysed via DNA extraction from 
paraffin embedded material.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 34 of 56 
 
 
     Version 9.0   
Sample Shipment 
 
Archival samples and paraffin embedded material should be sent at ambient temperature. Both kinds of specimens 
should be shipped to the Correlative Studies Program at the Princess Margaret Cancer Centre (see below).  Samples 
and inventory sheet must be shipped by overnight delivery in the designated shipping container.  Shipment must be 
scheduled for a Monday, Tuesday or Wednesday only. 
 
Archival and fresh tumor specimens should be shipped to: 
Correlative Studies Program 
Princess Margaret Cancer Centre 
610 University Ave 9-718 
Toronto, On 
M5G 2M9 
Phone : 416-946-4501 ext. 5047 
Fax : 416-946-4431  
 
14 SERIOUS ADVERSE EVENT REPORTING  
Adverse events (AE) will use the descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE). This study will utilize the CTCAE Version 3.0 for adverse event reporting. All 
appropriate treatment areas should have access to a copy of the CTCAE Version 3.0.  
 
All serious adverse events (SAE) defined as per ICH guidelines and other adverse events must be recorded on case 
report forms.  
 
14.1 Definition of a Reportable Serious Adverse Event  
• All serious adverse events, which are related to protocol treatment, must be reported in an expedited manner  
• A serious adverse event (SAE) is any adverse event that at any dose:  
• results in death  
• is life-threatening  
• requires inpatient hospitalization or prolongation of existing hospitalization (excluding hospital admissions for study 
drug administration, transfusional support, scheduled elective surgery and admissions for palliative or terminal care)  
• results in persistent or significant disability or incapacity  
• is a congenital anomaly/birth defect  
Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in other 
situations such as important medical events that may not be immediately life-threatening or result in death or 
hospitalization but may jeopardize the patient or may require intervention to prevent one of the events listed above.  
 
 
14.2 Reporting requirements 
 
Any serious adverse reaction must be reported to the DDP Central Office within 24 hours.  A completed SAE form will 
be submitted immediately to the DDP Central Office. The adverse experience must be completely described in the case 
report form. 
 
All serious unexpected adverse drug reactions must also be reported by the DDP Central Office to Health Canada 
within 15 days if the reaction is neither fatal nor life threatening, and within 7 days if the reaction is fatal or life 
threatening. 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 35 of 56 
 
 
     Version 9.0   
As Princess Margaret Cancer Centre is the sponsor of this study, the Principal Investigators of this study will be 
responsible for reporting all serious unexpected adverse events to Health Canada.  All serious adverse events occurring 
should also be reported to the local REB. 
 
All adverse signs and symptoms which occur during or following the course of drug administration must be reported in 
detail on the subject’s case report form.  This description is to include the nature of the sign or symptom, time of onset 
in relation to drug application, duration, severity, possible relationship to drug, required therapy, and outcome.  The 
subject should be followed until the adverse reaction is resolved, or until in the opinion of the Principal Investigator 
reversal of the reaction is not likely to occur. 
 
Any SAE will be reported to Pfizer Inc. at the Pfizer’s Canadian Safety Desk at fax # 1-877-526-7233.  For questions 
related to safety reporting, the Pfizer’s Canadian Safety Desk can be reached at telephone # 1-866-723-7111. All SAE 
and pregnancy reports, where the patient has been exposed to the Pfizer investigative Drug, will be sent to Pfizer Inc.  
SAE and pregnancy reports must be transmitted to Pfizer Inc. within 2 working days of awareness date. 
 
(a) 
SAE Definition.  An SAE is any adverse event, without regard to causality, that is life-threatening or that results 
in any of the following outcomes: death; in-patient hospitalization or prolongation of existing hospitalization; persistent 
or significant disability or incapacity; or a congenital anomaly or birth defect.  Any other medical event that, in the 
medical judgment of the Sponsor-Investigator, may jeopardize the subject and/or may require medical or surgical 
intervention to prevent one of the outcomes listed above is also considered an SAE.  A planned medical or 
surgical procedure is not, in itself, an SAE.  
(b) 
SAE Reporting Period.  The SAEs that are subject to this reporting provision are those that occur from after the 
first dose of the Pfizer Product through 28 days after discontinuation of the Pfizer Product (the "SAE Reporting 
Period"). 
(c) 
Follow-Up Information. Sponsor-Investigator and Institution will assist Pfizer in investigating any SAE and will 
provide any follow-up information reasonably requested by Pfizer. 
(d) 
Regulatory Reporting. Reporting an SAE to Pfizer does not relieve Sponsor-Investigator nor Institution of 
responsibility for reporting it to regulatory authorities, as required. 
 
14.3 DDP Central Office Responsibility for Reporting Serious Adverse Events to Health Canada  
The DDP Central Office will provide expedited reports of on-study SAEs to Health Canada and Pfizer for those events 
which meet regulatory requirements for expedited reporting, i.e. events which are BOTH serious AND unexpected (as 
determined by reference to the Investigator Brochure), AND which are thought to be related to protocol treatment (or 
for which a causal relationship with protocol treatment can not be ruled out).  
 
14.4 Reporting Safety Updates to Local Research Ethics Boards  
DDP Central Office will notify Pfizer, Canada of all Serious Adverse Events (SAEs) from this trial that are reportable 
to regulatory authorities in Canada. This includes all serious events that are unexpected and related (i.e. possibly, 
probably, or definitely) to protocol treatment. Investigators must notify their Research Ethics Boards (REBs) and file 
the report with their Investigator Drug Brochure. Documentation as outlined below must be maintained for reportable 
SAEs.  Documentation that serious adverse events (SAEs) have been reported to REB must be forwarded to theDDP 
Central Office and kept on file at the centre. Documentation can be any of the following:  
 
 
letter from the REB acknowledging receipt  
 
stamp from the REB, signed and dated by REB chair, acknowledging receipt 
 
letter demonstrating the SAE was sent to the board. 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 36 of 56 
 
 
     Version 9.0   
Trial data will be entered into the DDP database from electronic case report forms.  Data submission requirements are 
detailed in Appendix VIII.   
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 37 of 56 
 
 
     Version 9.0   
15.0 ETHICAL, REGULATORY AND ADMINISTRATIVE ISSUES  
15.1 Institution Eligibility  
The lead centre for this study will be Princess Margaret Cancer Centre. 
 
15.2 Investigator Qualifications  
For all investigators (principal investigators and co-investigators) the following documentation must be on file with the 
Princess Margaret Cancer Centre Drug Development Program: 
• A current curriculum vitae, updated and submitted within two years prior to central activation of the trial.  
 
15.3 REB (Research Ethics Board) Approval for Protocols  
Each participating site will have available a description of its ethics review process and composition of its REB.  
 
Amendments/Administrative Updates  
All amendments or administrative updates to the protocol must undergo review by the local REB. If full board approval 
of an amendment is required it will be specified. 
 
Amendments will be reviewed and approved by Health Canada prior to central implementation of the amendment, and 
by the REB prior to local implementation, EXCEPT when the amendment eliminates an immediate hazard to clinical 
trial subjects. Amendments will be distributed with Health Canada REB attestation forms which must be completed. 
For each amendment DDP Central Office will collect documentation of REB approval, a completed REB attestation 
form, and the date the amendment is locally activated.   
 
Serious Adverse Events, Safety Updates and Investigator Brochure Updates  
During the course of the study serious adverse events, safety updates or investigator brochure updates may be sent for 
reporting to the REB. The date of REB submission for these documents will be documented with the DDP Central 
Office and must be retained in the study binder on site.  
 
15.4 Informed Consent  
Informed Consent Document  
 
The REB of an institution must approve the consent form document which will be used at that centre prior to its local 
activation; changes to the consent form in the course of the study will also require REB approval.  
 
Consent Process/Patient Eligibility  
 
Patients who cannot give informed consent (i.e. mentally incompetent patients, or those physically incapacitated such 
as comatose patients) are not to be recruited into the study. Patients competent but physically unable to sign the consent 
form may have the document signed by their nearest relative or legal guardian. Each patient will be provided with a full 
explanation of the study before consent is requested.  
 
15.5 Retention of Patient Records and Study Files  
ICH Good Clinical Practice guidelines apply to this study. It is the responsibility of the DDP Central Office to inform 
the investigator/institution as to when trial related records no longer need to be retained. The investigator/institution 
should take measures to prevent accidental or premature destruction of these documents.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 38 of 56 
 
 
     Version 9.0   
16.0 BACKGROUND THERAPEUTIC INFORMATION  
15.1 Name and Chemical Information; Sunitinib malate (NSC 736511)  
 
Chemical Name:  
5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl)-2,4dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-
ethyl)amide; compound with (S)-2-hydroxy-succinic acid.  
Other names: SU011248 L-Malate salt; SU010398; PHA-290940AD; Sutent;  
 
SU011248  
Classification: Receptor tyrosine kinase inhibitor (RTK)  
Molecular formula: C22H27FN4O2.C4H6O5 M.W.: 532.57 Daltons  
Physical description: Yellow to orange powder  
CAS registry number: 341031-54-7  
Aqueous solubility:  
Solvent Solubility (mg/mL); 0.1 M HCl 59.1; ph 4.5 buffer 25.4; ph 6.8 buffer 37.8; ph 7.5 buffer 0.05; In water 1.6  
Solubility in various solvents (mg/mL): Acetonitrile 0.1; Dimethyl sulfoxide 92.9; Tetrahydrofuran 0.2; Methanol 1.5;  
Ethanol 0.3; 1-Butanol 0.1; 1-Butano: Water (80/20 v/v) 6.2; N, N-Dimethylacetamide 37.0; N, N-Dimethylformamide 
18.4  
 
16.2 Chemical Structure  
 
16.3 Mechanism of Action  
Tumour VEGF expression has been associated clinically with disease prognosis in many different types of 
malignancies. VEGF expression is increased by diverse stimuli including proto-oncogene activation and hypoxia, with 
the hypoxic state frequently arising in solid tumours because of inadequate perfusion. In addition to its angiogenic role, 
VEGF also profoundly increases the permeability of the vasculature thereby potentially contributing to tumour 
progression. A leaky tumour endothelium enhances nutrient and catabolite exchange and represents less of a barrier to  
tumour cell migration and intravasation during metastasis. Two high-affinity receptors for VEGF with associated TK 
activity have been identified on human vascular endothelium, VEGFR-1/Flt-1 and VEGFR-2/kinase insert domain-
containing receptor (KDR). Although the relative contributions of KDR and Flt-1 signalling in mediating tumour 
progression have not been elucidated, a number of studies suggest that KDR performs a predominant role.  
 
In addition to VEGF receptor signalling, increasing evidence implicates PDGFR signalling in tumour angiogenesis. 
Recent nonclinical evidence suggests that inhibition of PDGFR signalling augments the antitumour and antiangiogenic 
effects of VEGFR inhibitors. In addition, PDGF signalling is implicated in the autocrine growth of tumour cells and in 
the recruitment and regulation of tumour fibroblasts.  
 
Upon chronic oral dosing, sunitinib is expected to inhibit PDGF- and VEGF-driven angiogenesis and as a consequence, 
limit solid tumour growth. Because angiogenesis is necessary for the growth and metastasis of solid tumours, and 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 39 of 56 
 
 
     Version 9.0   
VEGF is believed to have a pivotal role in this process, sunitinib treatment may have broad-spectrum clinical utility 
(Kim 2004; Arora and Scholar, 2005). Sunitinib also exerts direct anti-tumour activity on cells that express target RTKs 
associated with tumour cell proliferation, such as KIT, PDGFR and RET.  
 
15.4 Experimental Antitumour Activity  
In vitro studies have demonstrated the specificity of sunitinib for inhibition of the Class 3 and Class 5 RTKs including 
receptors for VEGF (VEGFR), KIT and Flt-3, and PDGFR (Investigator’s Brochure SU011248, 2008). Specifically, 
receptor phosphorylation inhibition studies have shown that sunitinib inhibits KIT-ligand-induced phosphotyrosine 
levels in a dose-dependent manner with IC50 values of 0.001-0.01 mcM in vitro and reduced PDGFR-• 
phosphotyrosine levels in vivo (Abrams 2003a). Sunitinib also selectively inhibited proliferation of human umbilical 
vein endothelial cells (HUVEC) stimulated with VEGF (IC50=0.04 mcM) compared to FGF-stimulated proliferation 
(IC50=0.7 mcM) (Mendel 2003).  
 
In animal efficacy studies, sunitinib showed broad antitumour activity in mouse xenograft models against a variety of 
human tumour cell lines including colorectal cancer (HT-29, Colo205), non-small cell lung cancer (H460), breast 
cancer (MDA-MB-435), melanoma (A375), epidermoid cancer (A431), and glioma (SF763T) (Mendel 2003). Sunitinib 
has also demonstrated antitumour activity against other breast cancer models (MMTV-v-Ha-ras transgenic mouse 
mammary carcinoma and dimethylbenzanthracene [DMBA]-induced rat mammary carcinomas) (Abrams 2003b). In an 
animal model of KIT-expressing small cell lung cancer (SCLC; NCI-H526), sunitinib administration resulted  
in greater tumour growth inhibition than did imatinib (Abrams 2003a). Additional nonclinical in vitro and in vivo 
studies are summarized in Sakamoto 2004.  
 
16.5 Clinical Experience  
As of December 2005, over 3500 subjects had received sunitinib in various clinical trials, with nearly 400 subjects 
having received the agent for at least 6 months (Personal Communication from Pfizer, December 2005). In phase I 
studies, sunitinib demonstrated single-agent activity in patients with renal cell carcinoma (RCC), gastro-intestinal 
stromal cell tumours (GIST), non-GIST sarcomas, non-small cell lung cancer (NSCLC), colorectal cancer, 
neuroendocrine tumours (NET), melanoma, prostate cancer, and thyroid cancer. Sunitinib has also been studied in the 
phase I setting in patients with acute myeloid leukemia (AML). Phase II development thus far has focused on single-
agent trials in metastatic RCC (MRCC), imatinib-resistant GIST, metastatic breast cancer (MBC), NSCLC, and  
carcinoid and islet cell NETs. Pivotal trials of sunitinib in imatinib-resistant GIST (a placebo-controlled phase III trial) 
and MRCC (single-arm, non-randomized, multicenter, open-label trial) and supporting trials in each disease have lead 
to approval of sunitnib by the FDA. In addition, there are several ongoing company-sponsored single agent and 
combination clinical trials for a variety of other indications.  
 
16.6 Pharmacokinetic and Pharmacodynamic Studies  
Clinical pharmacology studies of sunitinib demonstrate that Cmax and AUC increase in a proportional manner after 
single doses of 50-350 mg, as well as after multiple doses of 25-100 mg (Investigator’s Brochure SU011248, 2008). 
Cmax ranged from 26.0-48.7 ng/mL for the parent compound and from 4.3-8.9 ng/mL for the major metabolite, 
SU12662. AUC0-24 ranged from 389-819 ng•hour/ml for sunitinib and 52-140 ng•hour/mL for SU12662. Peak plasma 
concentrations of the metabolite were much lower than those of sunitinib but declined more slowly. The terminal 
elimination half-lives of sunitinib and SU12662 are approximately 40 hours and 80 hours, respectively. After 28 days 
of dosing, the AUC0-24 for sunitinib increased 2.5- to 3.5-fold, while AUC0-24 of SU12662 increased 4-to 12-fold 
compared to day 1. Plasma concentrations of sunitinib and SU12662 typically reach steady-state levels after 1 to 2 
weeks of dosing. Concentrations of parent drug and metabolite measured through 3 cycles of therapy have shown that 
Cmax, AUC0-24, and trough plasma drug concentrations during cycle 2 or cycle 3 were not increased above those 
observed in cycle 1.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 40 of 56 
 
 
     Version 9.0   
The major in vitro studies on metabolism enzymology have been conducted in human liver microsomes, human 
hepatocytes, and expressed human CYP enzymes. Sunitinib is primarily metabolized in human liver microsomes by 
cytochrome P450 (CYP) isoform 3A4 but appears to have minimal potential to inhibit CYP3A4-mediated metabolism, 
and studies in human hepatocytes indicated that neither sunitinib nor SU12662 induced CYP3A4. These studies suggest 
that sunitinib and SU12662 are unlikely to have any clinically relevant drug-drug interactions with drugs that are  
substrates for CYP3A4. Concurrent administration of sunitinib and ketoconazole, a potent CYP3A4 inhibitor, resulted 
in less than a 2-fold increase in sunitinib exposure (based on Cmax and AUC) and a small decrease in SU12662 
exposure (Washington 2003). However, concurrent administration of sunitinib and rifampin (a potent CYP3A4 
inducer) in healthy male Caucasian and Asian volunteers resulted in a 4-fold reduction in sunitinib plasma exposure 
(AUC) and a 2.5-fold reduction in plasma Cmax compared with sunitinib alone in both ethnic groups (Bello 2005).   
 
Biomarker analysis was performed on plasma samples taken predose on days 1 and 28 of each cycle from 63 patients 
with MRCC treated with 50 mg sunitinib daily on the 4/2 schedule (DePrimo 2005). After the first cycle, VEGF 
increased 3-fold in 24 of 54 patients compared to baseline, PIGF increased greater than 3-fold in 22 of 55 patients, and 
sVEGFR2 levels decreased by 30% in 50 of 55 patients. In addition, longitudinal decreases in sKIT were observed in 
most cases. Results from this study indicate that analysis of circulating proteins may be of utility as pharmacodynamic 
biomarkers of sunitinib activity.  
 
16.7 Safety Issues  
The most frequent adverse events (AEs) seen following sunitinib treatment are constitutional (fatigue/asthenia), 
gastrointestinal (nausea, vomiting, diarrhoea, abdominal pain, anorexia, stomatitis, dysgeusia) and hematologic 
(neutropenia, thrombocytopenia) as well as skin discoloration (Investigator’s Brochure SU011248, 2008). Most of the 
AEs are grade 1 or 2, but at 75 mg daily on an early phase I trial, grade 3 and 4 fatigue/asthenia were dose-limiting but 
readily reversible on discontinuation of treatment (Rosen 2003). These investigators noted that the frequency and 
severity of AEs appeared to correlate with higher drug exposure or with lower performance status of the patients.  
In another phase I study, grade 3 fatigue and hypertension were dose limiting at 59 mg/m2 and the MTD was defined as 
42 mg/m2 daily (Raymond 2003). Tumour responses in patients treated at higher doses on this study were often 
associated with reduced intratumoral vascularization and central tumour necrosis which led to organ perforation in one 
patient and fistula in another. These observations indicate the necessity for careful tumour density monitoring to detect 
early evidence of necrosis. Rapid destruction of bulky solid tumours can occur following sunitinib treatment, with  
pneumothorax, intestinal fistulae, or intestinal perforation each occurring at an incidence of less than 1.5% of patients. 
Across all patient populations, fatigue, hematologic AEs, and lipase elevations were the most common grade 3 and 4 
events.  
 
In addition to the frequent AEs noted above and those which are infrequent but severe, the following events have 
occurred: grade 2 edema and oral ulceration in AML (Fiedler 2005); transient grade 3 and 4 hypertension, 
asymptomatic lipase increases (with or without amylase elevations), skin irritation in imatinib-resistant GIST (Desai et 
al., 2004); and grade 3/4 glossodynia in the NET trial (Kulke 2005).  
Additional reports from the manufacturer include anemia, pyrexia, and dyspnea in AML; and abdominal pain, 
dyspepsia, skin discoloration, headache, constipation, dermatitis, increased lipase, limb pain, and taste disturbance in 
various solid tumour patients (Investigator’s Brochure SU011248, 2008). Of interest, dyspepsia, dysgeusia, and 
stomatitis were reported twice as often in MRCC as in GIST, although these events occurred in both populations.  
 
Fatal bleeding possibly related to their disease occurred in two patients with AML (one from concomitant lung cancer, 
the other from a cerebral bleed) (Fiedler 2005). Both of the AML patients treated at the 75 mg dose level on this trial 
experienced dose-limiting AEs including grade 4 fatigue and hypertension; one of these patients (who had received 
prior mitoxantrone) developed cardiac failure. Other hemorrhagic events have occurred among patients receiving 
sunitinib for MRCC and GIST (SUTENT package insert). Although epistaxis was the most common hemorrhagic AE  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 41 of 56 
 
 
     Version 9.0   
reported, bleeding events also occurred in several other organ systems. Tumour-related hemorrhage can occur with 
sunitinib and in the case of pulmonary tumours, may present as severe and life-threatening hemoptysis or pulmonary 
hemorrhage.  
 
The incidence of cardiac AEs in patients receiving sunitinib has been investigated by the pharmaceutical company 
(Company Communication, December 2005):  
 
• Evaluation of data from 1356 subjects with solid tumours exposed to sunitinib for whom there are AE data (as of June 
2005) shows a combined incidence of 0.4% for cardiac events [including cardiac failure, cardiac failure NOS, cardiac 
failure congestive, or left ventricular failure as described by the NCI Common Toxicity Criteria (CTC) 2.0].  
• In an early dose-escalation study of sunitinib involving 32 subjects with AML, three cases of congestive heart failure 
were reported. Each subject had received high sunitinib doses (75 or 100 mg daily), and two of the three subjects had 
previously received anthracycline-based chemotherapy (cytarabine, idarubicin, daunorubicin, cyclophosphamide, and 
mitoxantrone).  
• After LV monitoring was implemented in sunitinib trials (including echocardiogram or multiple gated acquisition 
scans, cardiac enzyme measurements, and AE rates), a review of the data from the GIST and RCC clinical studies was 
subsequently conducted to identify whether changes in the LVEF (left ventricular ejection fraction) correlated with the 
clinical diagnosis of heart failure (congestive heart failure, cardiac failure, or LV failure) as reflected in reported AEs. 
In two MRCC studies (n=169), 25 patients (15%) had decreases in left ventricular ejection fraction (LVEF) to below 
the lower limit of normal (LLN). In a placebo-controlled, phase III GIST study (n=312), 22 patients (11%) receiving 
sunitinib and 3 receiving placebo (3%) had treatment-emergent LVEF values below the LLN. Nine of 22 GIST patients 
on sunitinib recovered without intervention, and 5 patients had documented LVEF recovery following intervention 
(dose reduction - 1 patient, addition of antihypertensive or diuretic medication - 4 patients). Six patients went off study 
without documented recovery. Additionally, 3 patients (1%) on sunitinib had grade 3 reductions in left ventricular 
systolic function to LVEF < 40%; two of these patients died without receiving further study drug. No GIST patients on 
placebo had Grade 3 decreased LVEF. One (<1%) patient on sunitinib and one (1%) patient on placebo died of 
diagnosed heart failure; two (1%) patients on sunitinib and two (2%) patients on placebo died of treatment-emergent 
cardiac arrest.  
• Cardiac enzymes CK-MB, cTnT, or cTnI were measured in over 200 subjects receiving sunitinib with the expectation 
that an elevation in cTn accompanying a decline in LVEF would suggest a drug-induced myocardial injury. In contrast, 
lack of correlation with cTn would be expected from conditions that induce (1) transient effects on LVEF, such as 
altered preload resulting from dehydration or (2) effects on myocardial contractility without significant myocardial cell 
injury. Viewed in the aggregate, the composite clinical data showed no consistent correlation between cTn elevations 
and decreases in LVEF, suggesting that LVEF declines associated with sunitinib treatment were not indicative of a 
drug-induced myocardial injury. In summary, intensive and prospective cardiac monitoring in 288 subjects receiving 
sunitinib has not identified major clinical cardiac AEs at the starting daily dose level of 50 mg (Schedules 2/2 or 4/2).  
While 8 (2.8%) of these 288 subjects developed significant decreases in LVEF, the evaluation of causality was 
confounded by comorbidities and the lack of a control population. None of these 8 events was of Grade 4 severity or 
associated with a fatal outcome. In addition, a correlation between LVEF decreases and drug exposure could not be 
established. Follow-up extending to 6 or more cycles in over 170 subjects showed no trend in cardiac AEs or 
cardiotoxicity serum biomarkers to suggest a cumulative or long-term adverse effect of sunitinib on cardiac function. 
Taken together, these findings suggest no increased risk of significant clinical cardiac toxicity for subjects with solid  
malignant tumours who will be receiving sunitinib treatment in future clinical studies. Moreover, serial and routine 
LVEF measurements do not appear justified except for patients with known risk factors for cardiac AEs (e.g., NYHA 
Class II dysfunction at entry or with a history of Class II dysfunction, prior anthracycline exposure, or central thoracic 
irradiation).  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 42 of 56 
 
 
     Version 9.0   
Although QTc-interval prolongation has not been observed in clinical trials, preclinical (in vitro and in vivo) studies 
indicate that sunitinib has the potential to inhibit the cardiac action potential repolarization process and prolong QTc 
(Investigator’s Brochure SU011248, 2008).  
 
Nonclinical evidence of adrenal toxicity following sunitinib exposure led the company to perform specialized safety 
assessments in clinical studies, including computed tomography or MRI in 365 subjects (as of July 2005) to specifically 
identify any change in adrenal gland structure or the presence of adrenal gland hemorrhage (Investigator’s Brochure 
SU011248, 2008). Neither event was observed. Based on available clinical AE safety data and radiologic and 
laboratory test results in patients treated with sunitinib, a total of, 6 of 1439 had AEs of adrenal insufficiency but 
without definitive causal relationship to the agent. Furthermore, no cases of drug-related hypocorticism requiring 
corticosteroid replacement therapy have been observed in clinical studies. However, based on the nonclinical findings, 
patients receiving sunitinib should be clinically followed for signs and symptoms of adrenal insufficiency, especially 
(1) patients with comorbidities associated with adrenal dysfunction, (2) patients with pre-existing adrenal insufficiency 
(primary or secondary), and (3) patients with concomitant stress (e.g., fever, infection, bleeding, serious accident, 
surgery) that may precipitate overt adrenal insufficiency in the presence of subclinical sunitinib-induced adrenal  
toxicity.  
 
Many of the kinase inhibitors including sunitinib, sorafenib, imatinib, and the epidermal growth factor receptor (EGFR) 
inhibitors produce a variety of cutaneous side effects that, while not life-threatening, can be very troublesome to the 
patient (Robert 2005). As presented in this review, hair depigmentation, splinter subungual hemorrhages, acral 
erythema, and facial edema (occasional) are some of the dermatologic adverse effects seen with sunitinib. Because the 
severity of certain cutaneous effects appears to correlate with antitumour response in the case of the EGFR inhibitors,  
there is interest in further elucidating the mechanisms whereby kinase inhibitors produce these effects and in the 
potential for identification of predictive factors.  
 
16.8 Rationale for Starting Dose and Schedule for Phase II  
Starting doses in multiple-dose studies were 25, 50, 75, and 100 mg administered orally once daily with the majority of 
patients receiving the 50-mg dose. Patients in sunitinib studies have been treated on four different schedules: schedules 
4/1 and 4/2 comprised 4 consecutive weeks of daily dosing followed by a 1- or 2-week rest period, respectively, while 
schedules 2/1 and 2/2 comprised 2 consecutive weeks of daily dosing followed by a 1- or 2-week rest period, 
respectively. The majority of subjects were treated on schedules 4/2 or 2/2 in phase I studies. Schedule 4/2 has been 
well tolerated with generally mild to moderate adverse effects at a 50 mg daily dose. Therefore, the recommended 
starting dose of sunitinib for this study is 50 mg daily administered on schedule 4/2 (daily for 4 consecutive weeks on 
followed by 2 weeks off).  
 
16.9 Pharmaceutical Data  
Supplied: Sunitinib malate is supplied by as 12.5 mg, 25 mg, and 50 mg capsules with mannitol, croscarmellose 
sodium, povidone, and magnesium stearate. Each opaque plastic bottle contains 28 capsules.  
 
Capsule strength Description  
12.5 mg Swedish Orange, Size 4 hard gelatin capsule  
25 mg Swedish Orange/Caramel, Size 3 hard gelatin capsule.  
50 mg Caramel, Size 2 hard gelatin capsule  
 
Stability: Shelf life stability studies for sunitinib capsules are ongoing.  
Storage: Store at controlled room temperature (15ºC to 30ºC), and protect from light.  
Route of Administration: Oral. Sunitinib malate may be administered without regard to meals.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 43 of 56 
 
 
     Version 9.0   
Patient Care Implications: A yellow discoloration of the skin area may result following direct contact with the capsules. 
Wash the exposed area with soap and water immediately.  
For drug interaction information please see protocol sections 8.4 and Appendix VI. 
 
16.10  
Adverse Events  
See Section 14.0 for adverse events and reporting requirements.  
 
16.11  
Potential Drug Interaction  
Sunitinib malate is metabolized primarily by liver enzymes, particularly CYP3A4. CYP3A4 inducers (e.g., rifampin, 
dexamethasone) and CYP3A4 inhibitors (e.g., grapefruit juice, ketoconazole) should be avoided, and certain potent 
inhibitors and inducers are contraindicated. Rifampin lowers sunitinib malate Cmax concentration by more than 2-fold. 
Ketoconazole increases sunitinib malate Cmax by 1.6 fold. Dose reduction with the CYP3A4 inhibitors is 
recommended, based on clinical symptoms. Concomitant treatment with dysrhythmic drugs, i.e., terfenadine, quinidine, 
procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide, is not  
recommended.  
 
See specific instructions regarding permitted / not permitted co-medication for this study in section 8.4.  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 44 of 56 
 
 
     Version 9.0   
 
17.0 REFERENCES  
Abrams TJ (a), Lee LB, Murray LJ, et al. SU11248 inhibits Kit and platelet-derived growth factor  
receptor-ß in preclinical models of human small cell lung cancer. Mol. Cancer Therap. 2003; 2:471-478.  
Abrams TJ (b), Murray LJ, Presenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor  
SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the  
treatment of breast cancer. Mol. Cancer Therap. 2003; 2:1011-1021.  
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;  
315(3):971-9.    
Canadian Cancer Statistics 2005. Canadian Cancer Society, National Cancer Institute Of Canada,  
Statistics Canada, Provincial/Territorial Cancer Registries, Public Health Agency Of Canada.  
http://www.cancer.ca.   
Demetri GD,Van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind,  
placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST.  
Proc. Am. Soc. Clin. Oncol 2005; 23: 308s (abstr. 4000).  
Demetri, GD, J. Desai, J.A. Fletcher, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can  
overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with  
metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2004; 22:14s (July 15  
Supplement) (abstr. 3001).  
DePrimo S, Bello C, Smeraglia J, et al. Soluble protein biomarkers of pharmacodynamic activity of the  
multi-targeted kinase inhibitor SU 11248 in patients with metastatic renal cell cancer. Proc Amer Assoc  
Cancer Res 2005; 46 (abstr 464).  
Desai J, Maki R, Heinrich MC, et al. Activity and tolerability of the multi-targeted tyrosine kinase  
inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to  
imatinib mesyalte. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium 2004; (abstr. 7).  
Dileo P, Van Den Abbeele AD, Manola J, et al. Qualitative assessment of 18FDG-PET correlates with  
clinical benefit in patients (pts) with imatinib mesylate (IM)-resistant GIST treated with the multi-targeted  
tyrosine kinase inhibitor SU11248. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium 2005;  
(abstr. 8).  
Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel  
oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006; 24:25-35.  
Fiedler W, Serve H, Döhner H et al. A phase 1 study of SU11248 in the treatment of patients with  
refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the  
disease. Blood 2005; 105:986-993.  
Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143  
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during  
tumorigenesis. Cell. 1996; 86:353-364.  
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, and Thun MJ. Cancer  
Statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.  
Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the  
growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 2004; 21(2):107-18.  
Kulke M, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in  
patients (pts) with unresectable neuroendocrine tumors (NETS). Proc Am Soc Clin Oncol. 2005; 23:310s  
(abstr. 4008).    
Mendel DB, Laird AD, Xin X, et al. In Vivo antitumor activity of SU11248, a novel tyrosine kinase  
inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors:  
determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9:327-337.  
Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU11248, a multi-targeted receptor tyrosine  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 45 of 56 
 
 
     Version 9.0   
kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) Proc.  
Amer. Assoc. Clin. Oncol. 2005; 23:16s (563).  
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of  
vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with  
metastatic renal cell carcinoma. J Clin Oncol. 2006; 24:16-24.  
Motzer RJ, Rini BI, Michaelson MD, et al. The SU11248 Study Group Phase 2 trials of SU11248 show  
antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Proc.  
Am. Soc. Clin. Oncol. 2005; 23:16s (4508).  
O’Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of  
FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003; 9:54655476.   
Raymond E, Faivre S, Vera K, et al. Final results of a phase I and pharmacokinetic study of SU11248, a  
novel multi-target tyrosine kinase inhibitor in patients with advanced cancers. Proc Am Soc Clin Oncol  
2003; 22: 192 (abstr. 769).  
Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies.  
Lancet 2005; 6:491-500.  
Rosen L, Mulay M, Long J, et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced  
solid tumors. Proc Am Soc Clin Oncol 2003; 22:191 (abstr. 765).  
Rustin G, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S,  
Greven K, Vergote I, Cervantes A, Vermorken J. New Guidelines to evaluate the response to treatment in  
solid tumors. J Natl Cancer Inst March 2004; 96(6):487-488.  
Sakamoto KM. SU-11248. Sugen. Curr Opin Invest Drugs 2004; 5:1329-1339.  
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, 
Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe, Verweij. New response evaluation criteria in solid tumours: 
Revised RECIST guideline (version 1.1).  Eur J Cancer 2009; 45:228-247.   
Washington C, Eli M, Bello C, et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on  
SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects. Proc Am Soc Clin Oncol.  
2003; 22:138s (abstr. 553).   


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 46 of 56 
 
 
     Version 9.0   
 
 
APPENDIX I – STUDY CALENDER 
 
Pre-
Study 11 
Cycle 1------------------------------------ 
Cycle 2+------------------------------------ 
Off 
Stu
dy12 
Wk 
116 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
5 
Wk
6 
Wk 
716 
Wk 
8 
Wk 
9 
Wk 
10 
Wk 
11 
Wk 
12 
Informed 
Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical 
History 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concurrent 
Meds 
X 
X………………………………………………………………………......................X 
 
Physical Exam1 
X 
X 
 
 
 
 
 
X 
 
 
 
 
 
X 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight1 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Performance 
Status1 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Urine 
Pregnancy 
Test2 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBC w/diff, 
platelets 
X 
 
X8 
 
 
 
 
 
 
PT/INR/PTT3 
X 
Twice a week 
As clinically indicated 
 
Chemistry4 
X 
 
 
 
 
 
 
X8 
 
 
 
 
 
X 
TSH, T4, 
Amylase, 
Lipase 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
Urinalysis 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
BP and HR 
measurement5 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
EKG 
X13 
 
 
 
 
 
 
X9 
 
 
 
 
 
 
LVEF-MUGA6 
X13 
 
 
 
 
 
 
X9 
 
 
 
 
 
 
Endocrine 
testing  
X 
 
 
 
 
 
 
X9 
 
 
 
 
 
 
Primary 
archival tissue 
block 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse Event 
evaluation7 
Base- 
line 
sympto
ms 
X…………………………………………………………………….........................X 
X 
Clinical tumour 
measurement 
X 
Repeated every 12 weeks (2 cycles). 15  
Documentation (radiologic) must be provided for patients removed from study for 
progressive disease. 
X10 
Radiologic 
evaluation 
X14 
Every 12 weeks (2 cycles) 15 
X10 
 
1 Can be once per cycle at physician’s discretion for cycle 3+ 
2 Only for women of childbearing potential 
3 Only for patients receiving low dose anticoagulants or LNW heparin 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 47 of 56 
 
 
     Version 9.0   
4 Albumin, ALP, Total Bilirubin, Bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphate, 
potassium, total protein, AST, ALT, sodium, calculated creatinine clearance (required only if serum creatinine >ULN, 
using cockcroft formula), CPK 
5 Weekly for cycle 1 then day 1, 15, 29 for cycle 2-3, then can be once per cycle at physician’s discretion. Repeat daily 
if BP > 150/100mm HG if previously within normal limits, or recurrent, persistent (>24 hrs) or symptomatic increase > 
20 mm Hg and manage as per protocol. Measurements may be performed more frequently at physician’s discretion. 
6LVEF measurements necessary for patients with class 2 NYHA, piror anthracycline or central thoracic radiation, and 
at investigator’s discretion in patients without cardiac risk factors 
7Adverse events will be recorded and graded using NCI Common Terminology Criteria for Adverse Events version 3 
(CTCAE) 
8Hematology and biochemistry should be repeated day 1 each cycle prior to sunitinib treatment 
9EKG, MUGA, endocrine testing (urinary metanephrines, catecholamines, serum chromogranin A) should be repeated 
on day 1, every two cycles. 
10 Off study radiologic / tumour measurements is required to confirm response in a patients who go off study with a PR 
or CR 
11Within 7 days prior to registration 
12 4 weeks off protocol  
13Within 21 days of registration 
14Within 28 days of registration 
15At investigator discretion, frequency of CT imaging can be decreased from every 12 weeks to every 4 months (+/- 2 
weeks) for patients receiving ongoing study treatment with responding or stable disease. 
16Measurements do not have to be repeated Cycle 1 Day 1, if screening visit occurred ≤ 3 days prior; All cycle day 1 
assessments must be within 7 days prior to cycle day 1


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 48 of 56 
 
 
     Version 9.0   
APPENDIX II - PERFORMANCE STATUS SCALES/SCORES  
 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 49 of 56 
 
 
     Version 9.0   
APPENDIX III - DRUG DISTRIBUTION, SUPPLY AND CONTROL  
 
The drug will be supplied by Pfizer Canada and distributed to the Princess Margaret Cancer Centre pharmacy in 
accordance with standard practice. 
 
APPENDIX IV- NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS  
VERSION 3.0 (CTCAE)  
 
This study will utilize the NCI Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) for adverse 
events and serious adverse event reporting. A copy of the CTCAE Version 3.0 can be downloaded from the CTEP 
home page: http://ctep.cancer.gov/reporting/ctc.html. All appropriate treatment areas should have access to a copy of 
the CTCAE Version 3.0.  
 
APPENDIX V - NEW YORK HEART ASSOCIATION CLASSIFICATION OF CARDIAC DISEASE  
 
 
 
 
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 50 of 56 
 
 
     Version 9.0   
APPENDIX VI – CYP450 METABOLIZED DRUGS  
Note: Potent inhibitors/inducers which are prohibited are bolded and must be discontinued/ withheld prior 
to patient enrolment as per protocol sections 5 and 7 and during study.  For other agents on this list, careful 
attention to toxic effects is recommended, but no discontinuation of medication is required. 
 
 
CYP3A4 
 
 
Substrates 
Inhibitors 
Inducers 
Generic Name 
Trade Name 
Generic Name 
Trade Name 
Generic Name 
Trade Name 
Anti-neoplastics: e.g 
Docetaxel 
Gefitinib 
Irinotecan 
 
Taxotere 
Iressa 
Camptosar 
Anti-arrhythmics: e.g. 
Amiodarone 
Diltiazem 
Quinidine 
 
Cordarone, Pacerone 
Cardizem, Dilacor XR 
Cardioquin 
Aminoglutethimide 
Cytadren 
Anti-virals: e.g 
Amprenivir 
Rifampin 
 
Agenerase 
Rifadin 
Anti-virals: e.g. 
Amprenavir 
Indinavir 
Nelfinavir 
Ritonavir 
Atazanafir 
Delaviridine 
Efavirenz 
Saquinavir 
 
Agenerase 
Crixivan 
Viracept 
Norvir 
Reyataz 
Rescriptor 
Sustiva 
Fortofase, Invirase 
Antibiotics : e.g. 
Rifabutin 
Rifampin 
 
Mycobutin 
Rifadin 
Anxiolytics: e.g 
Diazepam 
Sertraline 
 
Valium 
Zoloft 
 
Cimetadine 
 
Tagarnet 
Anticonvulsants: e.g. 
Carbamazapine 
Phenytoin 
Pentobarbital 
Phenobarbital 
 
Tegretol 
Dilantin 
Nembutal 
Luminal 
Cyclosporine 
Sandimmune 
Cyclosporin 
Sandimmune 
Hypericum perforatum 
St. John’s Wort 
Anti-infectives: e.g 
Erythromycin 
Tetracycline 
 
Erythrocin 
Sumycin 
Antibiotics: e.g. 
Ciprofloxacin 
Clarithromycin 
Doxycycline 
Enoxacin 
Isoniazid 
Telithromycin 
 
Cipro, Ciloxan 
Biaxin 
Adoxa, Periostat 
Penetrex 
Nydrazid, INH 
Ketek 
Anti-virals: e.g. 
Efavirenz 
Tipranavir 
 
Sustiva 
Aptivus 
Steroids: e.g 
Estrogens, conjugated 
Estradiol 
Progesterone 
 
Premari 
Climara 
Crinone 
 
Imatinib 
 
Gleevac 
 
 
Haloperidol 
Haldol 
Haloperidol 
Haldol 
 
 
Cardiovascular agents : e.g 
Digitoxin 
Quinidine 
 
Crystodigin 
Cardioquin 
Diclofenac 
Cataflam, Voltaren 
 
 
Anti-hypertensives : e.g 
Nicardipine 
Verapamil 
 
Cardene 
Calan, Chronovera 
Vasodilators : e.g. 
Nicardipine 
Verapamil 
 
Cardene 
Calan, Chronovera 
 
 
Anesthetics : e.g 
Ketamine 
Lidocaine 
 
Xylocaine 
Diprivan 
Anesthetics : e.g. 
Lidocaine 
Propofol 
 
Xylocaine 
Diprivan 
 
 
Nefazodone 
Serzone 
Anti-depressants : e.g. 
Nefazodone 
Sertraline 
 
Serzone 
Zoloft 
 
 
Cocaine 
 
Anti-fungals : e.g. 
Itraconazole 
Ketoconazole 
Miconazole 
voriconazole 
 
Sporanox 
Nizoral 
Lotrimin, Monistat 
VFEND 
 
 
Ketaconazole 
Nizoral 
Caffeine 
 
 
 
Sildenafil 
Viagra 
Grapefruit juice 
 
 
 
Albuterol 
Ventolin 
 
 
 
 
Carbamazapine 
Tegretol 
 
 
 
 
Lovastatin 
Mevacor 
 
 
 
 
When drugs classified as ‘substrates’ are co-administered with sunitinib there is the potential for higher concentrations of the ‘substrate’.  When sunitinib is co-
administered with compounds classified as ‘inhibitors’, increased plasma concentrations of sunitinib is the potential outcome.  The co-administration of ‘inducers’ 
would potentially lower plasma sunitinib concentrations. 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 51 of 56 
 
 
     Version 9.0   
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 52 of 56 
 
 
     Version 9.0   
 
Voriconazole 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 53 of 56 
 
 
     Version 9.0   
APPENDIX VII - COLLECTION/RECORDING OF BLOOD PRESSURE INFORMATION  
 
1.0 General Guidelines  
 
1.1 Frequency of Monitoring  
Blood pressure (BP) should be monitored weekly during the first cycle of sunitinib therapy, then at least every 2 weeks 
for the duration of treatment.  
 
1.2 Data Recording  
All required data should be recorded in the appropriate CRF or on the patient’s blood pressure monitoring diary, as 
appropriate. The following data are required at baseline and at each subsequent assessment:  
• Assessment date and time  
• Pulse  
• Systolic and diastolic BP (while patient sitting)  
• If patient’s BP is abnormal (i.e. >140/90), a second reading should be taken at least 5 minutes after the first reading. 
Both readings should then be recorded on the CRF  
 
1.3 Risk factors for hypertension (assess and record data in baseline CRF as appropriate)  
• Diabetes (type 1 or type 2)  
• Renal disease  
• Endocrine condition associated with hypertension  
• Use of steroids or NSAIDs (specify all concomitant meds on CRF)  
• Underlying cardiovascular condition – specify (i.e., ischemic heart disease)  
 
2.0 Baseline Data Collection (at study entry)  
 
2.1 All Patients  
• Current BP  
• Proteinuria, if present  
 
2.2 Patients with pre-existing hypertension (i.e., those for whom “hypertension” is entered as a concomitant condition 
(i.e. ‘other major medical problem’) at study entry, or those who are currently receiving therapy with antihypertensive 
medication) – also record:  
• Date of hypertension diagnosis (original)  
• Type hypertension (essential or secondary)  
• Actual BP value (at time of study entry)  
• Trade name, dose, dose frequency, start/stop dates/ongoing of the following:  
- Antihypertensive agents taken at study entry  
- Antihypertensive agents taken in past (e.g., discontinued for toxicity, lack of efficacy)  
  
3.0 Follow up BP Data Collection (during study)  
 
3.1 All patients (at each clinic visit)  
• Current BP  
• Proteinuria, if present  
 
3.2 Patients with treatment-emergent hypertension [defined as BP increase of >20 mmHg (diastolic) OR  


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 54 of 56 
 
 
     Version 9.0   
BP >150/100 (if previously within normal limits)] – record at time of hypertension diagnosis and at all subsequent 
clinic visits:  
• BP values (specify CTCAE v3.0 grade)  
• Hypertension-related symptoms as reported by patient (e.g., headache)  
• Other relevant changes associated with development of hypertension (e.g., ECG abnormalities)  
• Trade name, dose, dose frequency, start/stop dates/ongoing of currently prescribed antihypertensive agents  
 
3.3 Patients with pre-existing hypertension at study entry – record at each clinic visit: 
• Actual BP value  
• Hypertension-related symptoms reported by patient (e.g., headache)  
• Other relevant changes associated with development of hypertension (e.g., ECG abnormalities)  
• Changes in antihypertensive medications since last assessment (e.g., dose change, add/discontinue drug)  
Classes of antihypertensive drugs include ACE inhibitors, calcium channel blockers, alpha blockers, beta blockers, 
diuretics, angiotension II receptor antagonists.  
 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 55 of 56 
 
 
     Version 9.0   
APPENDIX VIII 
 
Case Report Form Submission Schedule 
 
Data required for the study will be collected in Case Report Forms provided by the Drug Development Program Central 
Office.  The site will be required to complete a paper Eligibility Checklist case report form (CRF) at the time of patient 
registration. All other data will be collected on electronic case report forms (eCRFs) in the Medidata Rave system. Site staff 
access to Medidata Rave will be initiated at the time of site activation. The form submission schedule is outlined below. The 
form submission schedule is outlined below. 
 
Case Report Form 
Submission Schedule 
Eligibility Checklist 
At the time of registration 
Baseline eCRFs 
Within 3 weeks of on study date 
On Treatment (Cycle) eCRFs 
Within 3 weeks of the end of each cycle of treatment 
Off Treatment eCRFs 
Within 3 weeks of the patient coming off-study 
Short Follow-up eCRFs 
Within 3 weeks of the patient coming to clinic.  Required every 3 months until 
death. 
Final Report eCRF 
Within 3 weeks of the patient's death being known to the investigator 
 
Case Report Form Completion 
 
The paper Eligibility Checklist must be completed using black or blue ink.  Any errors must be crossed out so that the 
original entry is still visible, the correction clearly indicated and then initialed and dated by the individual making the 
correction. 
 
eCRFs will be completed according to the schedule noted above. All patient names or other identifying information 
will be removed prior to sending any source documents to the Central Office. Instead, documents must be labeled with 
patient initials, study number and the protocol number.  eCRF completion guidelines are available for all sites.  
 Monitoring 
 
Data monitoring will take place throughout the trial. Data monitoring will be performed by Ozmosis Research Inc.   
Patient Registration 
 
 Prior to registering a patient, all necessary regulatory documentation must be submitted to the DDP Central 
Office.   
 No patient can receive protocol treatment until registration with the DDP Central Office has taken place.   
 The eligibility checklist must be completed and signed by the investigator prior to registration and faxed to the 
DDP Central Office.   
 There will be no exceptions to eligibility criteria allowed at the time of registration.  Any possible exceptions 
must be discussed in advance with the DDP Central Office and the Principal Investigator. 


SNIPP study Protocol – Knox et al., Princess Margaret Cancer Centre -Page 56 of 56 
 
 
     Version 9.0   
 Upon receipt of the completed eligibility checklist the DDP Central Office will confirm registration and issue a 
study number. This will then be confirmed in writing. 
Regulatory Requirements 
 
The following documents are required to be maintained at the DDP Central Office: 
 Canadian Principal Investigators must submit a completed Qualified Investigator Undertaking. 
 Up-to-date CVs of all investigators (signed within 2 years)  
 Laboratory certification/accreditation and normal ranges 
 Consent forms must be reviewed by the DDP Central Office before submission to the local ethics regulatory 
board (REB/IRB)  
 A Membership list of the local ethics board 
 A copy of the initial approval letter from the ethics board for the trial 
 Continuing annual approval until follow-up on patients is completed and no further data is being obtained for 
research purposes. 
 A completed Site Participant List/Training Log is required and must be submitted to the Drug Development 
Program Central Office  
 Investigators and site staff are required to complete Medidata eCRF training modules depending on delegated 
tasks